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ABSTRACT OF THE DISSERTATION

The Role of Glucocorticoid Signaling in Prostate Cancer Health Disparities
by
Leanne W. Burnham
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, June 2018
Dr. Carlos A. Casiano, Chairperson

African-American men are more likely to develop aggressive prostate cancer
(PCa) and die from the disease than other ethnic groups. Glucocorticoid signaling is a
contributing biological factor to worse PCa prognosis, and is emerging as a key driver of
PCa progression in the absence of androgens. The mechanism involves glucocorticoids
binding to glucocorticoid receptor (GR) and bypassing the androgen receptor (AR)
signaling pathway to activate AR-target genes that promote tumor aggressiveness and
therapy-resistance. This is problematic as African-American men have hypersensitive GR
signaling and chronically-elevated levels of glucocorticoids linked to cumulative stressful
life events. To explore the role of glucocorticoid signaling in PCa health disparities, this
dissertation used a racially diverse pre-clinical model to examine the effects of GR
activation on the expression of stress oncoproteins linked to tumor aggressiveness and
therapy-resistance, specifically Lens Epithelium-Derived Growth Factor p75
(LEDGF/p75) and Clusterin (CLU). Results revealed a robust pattern of GR-induced
upregulation of LEDGF/p75 and CLU in African-American (AA) PCa cells compared to
European-American (EA) PCa cells. We also detected increased GR transcript expression
in AA PCa tissues, compared to EA tissues, using Oncomine microarray datasets. In

xv

addition, a trend towards elevated circulating LEDGF/p75 and CLU was observed in sera
of AA patient samples. Taken together, these findings provide an initial framework for
understanding the contribution of GR signaling to PCa health disparities.
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CHAPTER ONE
INTRODUCTION
Prostate Cancer—Etiology, Stages, and Treatment Options
Cancer is a major worldwide health crisis and is the second leading cause of death
within the United States (U.S.).1,2 Among the different types of cancer, PCa is most
diagnosed in the U.S. and the second leading cause of cancer mortality.1 It is estimated
that 164,690 U.S. men will be diagnosed and 29,430 men will die from PCa in 2018.1
There are many underlying contributors to the development of PCa, but androgens (i.e.
testosterone) are the necessary driving factor necessary for disease development.3
Testosterone is produced by 2 distinct populations of testicular Leydig cells during the
fetal and adult developmental periods.3 At puberty, testosterone is converted to
dihydrotestosterone (DHT) within the prostate stimulating prostate growth.3 An eventual
homeostasis is achieved between prostatic cell differentiation and cell death resulting in a
maintenance of appropriate prostate size.3 Although endogenous testosterone levels
decrease as men age, prostatic cell proliferation increases resulting in prostatic disease
including PCa.3 This suggests an age-related altered response of prostatic cells to
androgens.3
Because testosterone function is dependent upon binding to androgen receptors
(AR), intraprostatic response of cells to androgens must depend on the expression and
sensitivity of ARs.3 The important role of AR extends beyond normal prostate function
and is an established main driver of prostate carcinogenesis and subsequent disease
progression.3 Because of this, targeting androgen production and AR has been a mainstay
of PCa treatment for over 7 decades.4 Dr. Charles Huggins initially demonstrated that
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both surgical castration and estrogen administration resulted in regression of PCa
metastasis.4 His pivotal findings pioneered the future development of many variations of
androgen deprivation therapy (ADT). Both agonists and antagonists of luteinizing
hormone-releasing hormone (LHRH) are typically used as a form of ADT meant to
decrease endogenous testosterone production through the hypothalamic-pituitarytesticular (HPT) axis. There have also been anti-androgens developed that bind to AR and
inhibit its activity including flutamide, bicalutamide, and nilutamide.5-7 Second-line antiandrogens Enzalutamide (Enz) and ARN509 have been developed for PCa patients who
have failed LHRH agonists/antagonists or other first-line antiadrogens.3
While ADT is initially successful in most PCa patients who choose this option,
ADT-resistance is inevitable occurring within 18-24 months.8 It is important to note that
prostatic epithelial cells demonstrate great plasticity in response to ADT giving rise to a
highly heterogeneous co-existence of AR-positive and AR-negative cells.3 Once a PCa
patient has developed ADT-resistance, he enters a disease stage referred to as metastatic
castration-resistant prostate cancer (mCRPC) which is incurable.9,10 The only therapeutic
strategies for mCRPC patients include taxane chemotherapy regimens docetaxel (DTX)
plus prednisone followed by cabazitaxel (CTX) plus prednisone or palliative options.11-13
While DTX and/or CTX can extend life by a few months, chemoresistance develops and
these treatments are not curative or long-lasting.11-13
PCa is initially detected and diagnosed in patients through a series of screening
procedures. Digital rectal examination (DRE) is performed manually by a physician
typically in a primary care setting.14 The purpose of DRE is to detect abnormal size of the
prostate as well as abnormal hard nodules. In most settings, the prostate-specific antigen
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(PSA) blood test is a complimentary screening tool to the DRE. PSA is produced by the
prostate and circulates at high levels in men with PCa.15 Circulating serum PSA levels are
considered abnormal when detected above 4 ng/ml.16 While the U.S. Food and Drug
Administration approved the use of PSA testing in conjunction with DRE to screen
asymptomatic men for PCa in 1994, the U.S. Preventive Services Task Force (USPSTF)
issued a recommendation against PSA-based screening in 2012.16 Conversely, the
American Cancer Society (ACS) recommends PCa screening at age 50 for men at
average-risk, 45 for men at high-risk, and 40 for men at higher-risk.17 In addition, ACS
recommends repeated annual PCa screening for men with PSA levels >2.5 ng/ml.17 While
the presence of high PSA is not always indicative of PCa, it is cause for follow-up
investigation including prostate biopsy.
Upon biopsy, a pathologist is able to detect PCa and assign a Gleason score which
is subsequently utilized by the patient’s physician to predict the aggressiveness of the
cancerous cells.18 The higher the Gleason score, the more likely the PCa will spread
rapidly.18 Gleason score ranges from 1-5 with an assignment of “1” representing small
uniform glands.18 A Gleason score of “3” represents moderately differentiated cells
where more space is visualized between glands with distinct infiltration of cells from
glands at the margins.18 A Gleason score higher than “3” represents poorly differentiated
and anaplastic cells with irregular masses of neoplastic cells and complete lack of
glands.18 Most PCa tumors score a grade of “3” or higher. Prostate biopsy results have
revealed vast PCa phenotypic heterogeneity. The predominant histological subtypes
found in prostate adenocarcinoma cells include luminal secretory, rare neuroendocrine,
basal, and luminal epithelial cells.19 And the trend towards heterogeneity continues

3

within the luminal epithelial cellular subtype.19 Because of this heterogeneity, 2 grades
are assigned to each patient by the pathologist to add to a final sum Gleason score
typically ranging from 6-10. Because of the enormous heterogeneity observed within and
among PCa patients there remains a monumental challenge to develop effective therapy
for this malignancy. Current options, including radical prostatectomy and radiation, can
be curative at early-stage diagnosis. However, treatment options for later-stage disease
including the aforementioned ADT and chemotherapy are not long-lasting (Figure 1).
This is problematic for men diagnosed with aggressive tumors or advanced PCa.
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PCa progression and treatment options
Localized PCa

Biochemical
Recurrence

Metastatic
castration-resistant
PCa (mCRPC)

Chemoresistant
mCRPC

• Watchful Waiting
• Radical
prostatectomy
• Radiation
• Proton therapy

• Primary androgen
deprivation
therapy (ADT)

• Secondary ADT
(Enzalutamide)
• Docetaxel (chemotherapy)
+ prednisone

• Cabazitaxel
(chemotherapy)
+ prednisone

Terminal

• Palliative care
• No current
effective
treatments

Figure 1. Stages and treatment options for PCa. There are a variety of treatment options
available for PCa at each stage. PCa is curable if eradicated while localized. However, once
tumor cells escape organ confinement, PCa is no longer curable and treatments are meant
to extend life. ADT is a treatment option at any stage of PCa, and is a mainstay course
recommended following biochemical recurrence. Castration-resistance occurs
approximately 18-24 months after primary ADT initiation. Late-stage PCa can be treated
with taxane chemotherapy as well as secondary ADT. Eventually chemoresistance
develops and palliative care is provided at the terminal stage.
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Prostate Cancer Health Disparities
AA men are 75% more like to be diagnosed with PCa and 228% more likely to
die from this malignancy than EA men.1 It is estimated that 1 in 8 EA men will be
diagnosed with PCa in their lifetime.20 However, the estimation rate in AA men is 1 in 6
and we recently reported that 1 in 3 AA men had elevated circulating PSA in a study that
recruited 414 AA men ranging from age 18-80.17,20 The biological characteristics of
prostate tumors are exaggerated in AA men compared to EA men at time of diagnosis,
including higher PSA levels, higher Gleason scores, and advanced tumor stage.21-23
The cause of these inequalities are complex and include many contributing factors
such as socioeconomic issues, biological and genetic determinants, diet, lifestyle, and
access to healthcare.20,24-30 Social and economic disparities directly affect diet, lifestyle,
access to healthcare, and therefore contribute greatly to differences observed in worse
cancer outcomes.20,31-33 Income inequalities lead to increased exposure to risk factors
such as barriers to high-quality cancer prevention, early detection, and cutting-edge
treatment options.20,31-33 Educational achievement affects potential income and in 2014,
22% of AAs had completed college while 36% of EAs had completed college.20 That
same year 26% of AAs were living below federal poverty level compared with 10% of
EAs.20 Less education leading to lower income affects neighborhood placement, and
lower socioeconomic neighborhoods are more likely to be targeted by marketing that
promotes behaviors known to increase cancer risk.20 There is also less access to healthy
fruits and vegetables as well as opportunities for physical activity.20 Socioeconomic
status translates to overall survival rates for several reasons that include limited access to
high-quality health care.32,34-36 Worse overall survival is compounded by the fact that
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AAs are more likely to be diagnosed at a later stage.20 Later diagnosis limits treatment
options and reduces the efficacy of those treatments.20 However, even when provided the
same PCa treatment as EA men, AA men are more likely to experience delay in treatment
administration and suffer greater postoperative complications.37 In addition, AAs are less
likely to participate in clinical trials preventing them from exposure to cutting-edge
options that could be more efficacious than widespread treatments.38,39 Comorbid
conditions affecting the delivery of optimal treatment must also be taken into
consideration, and these conditions including obesity, diabetes, and hypertension which
are higher in AAs.40-42
While socioeconomic factors largely contribute to cancer health disparities, we
cannot rule out the role that genetic and biological determinants play as these disparities
persist even after controlling for socioeconomic factors and access to care.43,44 PCa
exhibits the highest reported heritability compared to any other cancer,45-47 and genomic
differences between AA and EA men with PCa suggest genetic mediators are driving
PCa health disparities.48-56 Although most family-based linkage studies of hereditary PCa
have focused largely on European descent populations, a series of loci responsible for
PCa have been identified for AA men including 12q24, 1q24-25, 2p16, 2p21, and 1p36.57
Additional linkage signals detected in AA pedigrees include 2p21, 11q22, 17p11, 22q12,
and Xq21.58 Some loci have also been implicated in genome-wide association studies
(GWAS) and confirmed in AA men including 12q24, 1q24-25, and 8q24.59-61 Given that
loci detected by GWAS vs. family studies are not expected to be the same, evidence for
the role of these congruent genes in PCa etiology is further strengthened.62 Genetic
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variation on chromosome 8q24 has been consistently associated with PCa,60,62-65 and
ethnic specific mutations and haplotypes have been reported in African populations.64,66
In addition to inherited genomic factors linked to PCa, there are also somatic
alterations that are associated with the development of this disease.62 For example, gene
fusion TMPRSS2:ERG translocations have been found to be much lower in AAs (20%)
compared to EAs (62%).67 AA and EA men also have significant differences in ERG
expression.68 The prognostic value of TMPRSS2:ERG translocations and ERG
expression is not clear, but the relationship of PCa risk factors differs by TMPRSS2:ERG
translocation status.69-71 Therefore, the marker distribution may identify tumor
heterogeneity underlying PCa etiology and outcome disparities.62,67 In addition, the
association between obesity and worse PCa outcome has been found to vary by
TMPRSS2:ERG translocation status.72 By default, TMPRSS2:ERG translocation status
could drive tumor aggressiveness as AA men tend to have greater rates of obesity than
EA men.62
Gene expression and pathway profiles of PCa tumors have further confirmed
prominent differences in tumor immunobiology between AA and EA men.54 Genes
associated with autoimmunity and inflammation are differentially expressed in AA men
including genes clustering in immune response, stress response, cytokine signaling, and
chemotaxis pathways.54 Metastasis-promoting genes are also more highly expressed in
AA men including autocrine mobility factor receptor, chemokine receptor 4, and matrix
metalloproteinase 9.54 In a separate study, IL6, IL8, IL1B, CXCR4, and FASN were
significantly expressed at higher levels in tissue of AA men with PCa compared to EA
men.51 These are genes that have been associated with diet and lifestyle and are
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associated with higher Gleason scores, AR regulation, aggressive PCa tumors, and
metastasis.51,73-77 The differential expression of these genes is also consistent with
metabolic syndrome associated with comorbid health conditions such as hypertension and
obesity which AA men are more likely to suffer from.51
Given that androgens drive PCa etiology and disease progression prior to
mCRPC, several studies have explored differences in androgen production and AR
signaling in AA men compared to EA men.78-81 AA men have been found to have higher
testosterone levels than EA men.82 In addition, AA men have higher active 5-alpha
reductase levels resulting in enhanced conversion of testosterone to the more potent
DHT.83,84 The contrasting expression of epithelial and stromal AR in PCa tissue is
emerging as a possible driver of castration resistance in patients receiving ADT.78 Studies
exploring this possibility have observed that nuclear AR has found to be increased in AA
PCa patients,85 but stromal AR are decreased in AA compared to EA PCa patients.86,87 A
separate study examined the occurrence of AR mutations and polymorphisms and results
revealed that AA PCa patients have higher frequency of germline and somatic mutations
in AR.88 The expression of AR target genes such as PSA have also been found to be
increased in AA PCa patients.78,89,90 Other AR target genes including RHOA, ITGB5, and
PIK3CB are differentially expressed in tissue samples of AA PCa men compared to EA
PCa men and are associated with properties of PCa tumor aggressiveness including
increased invasion activity of cells.91
Taken together, there is substantial evidence that AA men are genetically
predisposed to develop PCa and with an aggressive tumor phenotype. In addition, the
socioeconomic factors which amplify this predisposition towards disproportionate PCa

9

incidence and mortality cannot be overlooked. Substantial progress has been made
towards addressing these PCa health disparities. However, there remains a need to
continue biomedical research targeting AA men with PCa while also promoting equitable
access to services for prevention, early detection, and high-quality treatments for this
disease.

African Americans and Stress
African Americans are exposed to more cumulative lifetime stressors than other
racial/ethnic groups and there is evidence that this detrimentally alters psychologic and
physical health.92-94 Chronic stress leading to the dysregulation of endogenous cortisol
production via the hypothalamic-pituitary-adrenocortical (HPA) axis in response to
chronic stress is a major biological phenomenon that can enhance risk for metabolic
disorders and cancer.92,94-96 The HPA axis regulates the human body’s response to
stress.97,98 When the HPA axis is activated in response to stress, neurons in the
paraventricular nucleus of the hypothalamus are triggered to release corticotropinreleasing hormone (CRH) and arginine vasopressin, which stimulate adrenocorticotropic
hormone (ACTH) production and secretion from the anterior pituitary gland (Figure
2).97,99 ACTH circulation induces the synthesis and secretion of cortisol, a glucocorticoid,
from the adrenal cortex (Figure 2).97,99 A classical endocrine negative feedback loop
inhibits further release of CRH and ACTH in response to rising levels of cortisol (Figure
2). In this manner, a physiological homeostasis is maintained under normal conditions.97
In addition, the HPA axis tightly regulates glucose metabolism, the cardiovascular
system, cell proliferation and survival, growth, cognition and behavior, immune function,
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and reproduction directly through cortisol production.97 Cortisol is secreted diurnally,
peaking after wakening when blood glucose levels are at the lowest and tapering
throughout the day.92 This diurnal rhythm is unfortunately altered in response to
chronically stressful situations (Figure 2).92,100 The stage is set for the initiation of
pathogenic processes when cortisol levels are either elevated or cease to taper
normally.92,101
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Figure 2. HPA axis regulation and negative feedback inhibition. The HPA axis tightly
regulates the production of endogenous cortisol. The HPA axis is stimulated by the diurnal
circadian rhythm as well as stressors. A normal negative feedback loop ensures
physiological
homeostasis
to
prevent
excess
cortisol
production.
(http://www.lapislight.com/wp/tag/hpa-axis/)
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Chronic exposure to stressors is increased in individuals of lower socioeconomic
status (SES) and there is a positive association between SES and stress in AA men.92,102
Decreased SES is defined by lesser income, education, or occupation and often results in
increased exposure to environmental stressors leading to stress-related dysregulation of
physiological systems and increased risk for disease.92,101,103 Even in AAs who have
achieved high SES, racial disparities in health persist.104 For example, a poor lipid profile
characterized by high triglycerides, LDL cholesterol, total cholesterol, and lower HDL
cholesterol, actually increases in AAs as education increases.105 Considering all factors,
AA men have the shortest life expectancy at 16 years less than EA women who benefit
from the longest life expectancy.106
SES and racial categories walk hand-in-hand and cannot be extricated from each
other in the context of U.S. history.106,107 National data reveals that strikingly high levels
of racial inequality in SES yet exist with little change over time and AAs continue to
suffer disproportionately lower SES.106 For example, AAs have overall poverty levels
that are two to three times higher than EAs.106 There is evidence that income does not
increase in AAs commensurately as education increases, and AA men with a master’s
degree earn $27,000 less than their EA counterparts.106 While the racial gap in education
between AAs and EAs has narrowed over time, the relative pay of AA men declined by
10% compared to EA men between 1979 and 1997, and AAs have 9 cents in wealth for
every dollar of wealth that EAs have.108 Furthermore, employed AAs are more likely to
be exposed to carcinogens and occupational hazards compared to others with matched
education and job experience.108,109 Compounding these realities, AAs have less
purchasing power as the costs of goods and services are highest in predominantly AA
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communities.108,109 Not surprisingly, the ensuing financial hardships translate to tangible
stressors such as the inability to meet essential expenses, pay full mortgage or rent, or pay
all utility bills.108
Outside of the workplace, AAs are exposed to daily stressors within their
segregated neighborhoods.106 The effects of segregated neighborhoods are vast and
negatively impact the health of AA residents.110,111 For example, segregation limits
access to quality education and limits socioeconomic mobility by impeding preparation
for higher education and lucrative employment opportunities.110,111 Optimal health is also
jeopardized in economically-disadvantaged segregated neighborhoods as nutrition suffers
in the presence of higher cost, lower quality, and lesser availability of healthy foods.110,111
Similarly, physical activity is reduced in the absence of recreational facilities amid safety
concerns.110,111 Exposures to environmental toxins and poor-quality living conditions are
also a reality in neighborhoods accustomed to institutional neglect and
disinvestment.110,111
Taken together, the stressors associated with lower income and issues arising
from segregated neighborhoods are directly linked to elevated risk of illness and death,
and greatly contribute to existing racial disparities in health.110,112 Individuals living in
census tracts with elevated rates of unemployment and poverty have been shown to have
diminished central nervous serotonergic activity leading to increased risk of depression
and substance abuse.113 Adding to these stressors many AAs face on a daily basis are
perpetual experiences of discrimination.106,114 An association has been firmly made
between experiences of discrimination and adverse health effects including sexual
dysfunction, less stage 4 sleep, increased abdominal fat, elevated hemoglobin A1c,
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coronary artery calcification, increased uterine myomas, and cancer incidence.115
Perpetuating the cycle of substance abuse, exposure to discrimination reduces health care
seeking behaviors and increases tobacco, alcohol, and illicit drug use.115
As AAs are disproportionately arrested by law enforcement and subsequently
incarcerated than any other racial/ethnic group, recent studies are exploring the impact of
these experiences on health.106,116,117 Incarceration is characterized as a “disorderly
transitional” stressful event that is undesired and involuntary, and promotes lasting health
effects including hypertension.117,118 Health is further compromised through a lifetime as
incarceration, at any point and for any amount of time, places an individual on a
trajectory of lower education, decreased job prospects, and income resulting in an
increase of other stressors.116-118
Social disparities in health are large, pervasive, and persistent in AAs and these
inequalities in health reflect larger inequalities in society.106 It is important to carefully
consider social risk factors to fully understand the biological processes shaping health
disparities.106 SES has been shown to influence emotions and behaviors which
subsequently alter cortisol levels.103 Lower SES is associated with greater perceived
stress, depressive symptoms, negative affect, weak social networks and support, and
sleep deprivation.92 Consequently, these factors are also linked to greater cortisol
responses.119-122 A major study by Cohen et al. explored whether SES-associated
dysregulation of cortisol diurnal rhythm is independent of race and occurs equally in AAs
and EAs.92 This study reported that individuals with higher education and income had
steeper declines in cortisol over the day in a diurnal slope resulting in lower cortisol
levels in the evening.92 Yet after controlling for education and income, AAs were found
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to wake with lower cortisol levels and sustain higher cortisol levels in the evening
suggesting a dysregulation of normal cortisol diurnal rhythm that cannot be explained by
differences in SES.92 The long-term consequences of this dysregulation are complicated
and problematic for the health of AAs.94,106,108

Glucocorticoid Signaling—Normal vs. Aberrant
Cortisol is an endogenous glucocorticoid produced by humans.97,99 Both cellular
and pharmacological actions of glucocorticoids are mediated by the glucocorticoid
receptor (GR).97 Alternative splicing produces 3’ UTR mRNA isoforms of GR—GR,
GR, and GRP.123 GR shuttles between the cytoplasm and nucleus to regulate
transcription, GR is localized in the nucleus and has a dominant negative effect on
GRupon forming GR/ GRheterodimers, and GRP has both a synergistic and
antagonistic relationship with GR The GR gene nuclear receptor subfamily 3
group C member 1 (NR3C1) is regulated by complex promoter regions containing
multiple transcription start sites and contains at least nine 5’ UTR first exons that are
spliced to exon 2 (Figure 3).123 The alternative first exons are divided into two promoter
regions, exon 1A and 1I, as well as a proximal region upstream of the translation start site
containing exons 1B, 1C, 1D, 1E, 1F, 1H, and 1J,123 and each first exon is regulated by its
own promoter (Figure 3).123,126,127
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Figure 3. GR isoforms. The GR is comprised of 9 exons. Alternative splicing of exon 9 at
the 5’ end of the coding region leads to the formation of the classic GR isoform and the
dominant negative GR isoform. The multiple exon 1 variants that control tissue-selective
gene expression are also shown. (Ito, Chung, and Adcock. J Allergy Clin Immunol. 2006.)
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As GRis the biologically relevant isoform, all references henceforth to GR will
imply GR GR is a member of the nuclear receptor superfamily of ligand-dependent
transcription factors. GR is made of three functional domains including an aminoterminal transactivation domain, a central DNA-binding domain, and a carboxy-terminal
ligand-binding domain.97 There is a flexible hinge region that contains a nuclear
localization signal between the DNA-binding domain and the ligand binding domain. It is
within this flexible hinge region that genomic interactions occur.97 GR is intracellularly
located within either the cytoplasm or the nucleus depending on the absence or presence
of ligand.97 Glucocorticoid ligands of GR can be endogenous (cortisol) or synthetic and
include hydrocortisone, dexamethasone (Dex), and prednisone.97 In the absence of ligand
binding, GR resides in the cytoplasm as part of a large multi-protein complex including
chaperone heat shock proteins hsp90, hsp70, and p23 as well as immunophilins of the
FK506 family including FK506-binding protein (FKBP) 51 and FKBP52 (Figure
4).97,128,129 Upon ligand binding, a conformational change occurs releasing GR from the
chaperone proteins and promoting nuclear localization of GR97
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How glucocorticoids operate in the cell
Glucocorticoids

Kino T, 2010. http://brainimmune.com/the-glucocorticoid-receptor/

Figure 4. Translocation of GR. Upon binding to ligand, GR dissociates from chaperone
proteins and translocates into the nucleus, where it regulates the transcriptional activity of
GR-target genes positively and negatively either by binding to GREs located in the GRtarget gene promoter region or by physically interacting with other transcription factors.
After completion of changing the transcriptional activity of GR-target genes, GR is
exported into the cytoplasm and is incorporated into the complex with chaperone proteins.
(Ito T. Brain Immune Trends. 2010.)
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Within the nucleus, GR homodimer binds to GR response element (GRE) DNA
sequences within target genes.130 The consensus GRE sequence is comprised of two
hexameric half-sites separated by a spacer of three nucleotides
(AGAACAnnnTGTTCT).131 Once GR homodimers bind to GREs, chromatin is
remodeled, co-regulators are recruited, and GR-induced transcription is initiated.97 In
addition to activation of GR-target genes, GR also negatively represses genes.132 This
occurs when GR binds to negative GREs with consensus sequence CTCC(n)0-2GGAGA
and co-repressors are recruited.132 GR also mediates gene transcription via heterodimer
binding interactions with other transcription factors.97
Both the nature and intensity of cellular response to glucocorticoids is dependent
upon a few factors including ligand dose and type, GR post-translational modifications,
relative abundance of co-regulators, chromatin environment, and GREs of GR-target
genes.133 Within peripheral tissues, GR stimulation is physiologically tightly regulated by
11-hydroxysteroid dehydrogenase-2 (11-HSD2) which enzymatically converts cortisol
to its inactive form cortisone in humans.134,135 Loss of 11-HSD2, mediated by the
ubiquitin E3-ligase autocrine mobility factor receptor, within peripheral tissues results in
sustained elevated cortisol and stimulates aberrant GR signaling.134
GR signaling also plays a major role in carbohydrate, lipid, and protein
metabolism.136,137 During periods of fasting, such as during sleep, glucocorticoids enable
maintenance of physiological blood glucose levels by decreasing glucose uptake in
muscle as well as stimulating hepatic glucose production via gluconeogenesis and
glycogenolysis.136,138 Glucocorticoid excess leads to several adverse effects including
impaired glucose homeostasis.136,139 This occurs specifically by enhancing hepatic
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glucose output by inducing enzymes regulating gluconeogenesis including glucose-6phosphatase, fructose-1,6-biphosphatase, and phosphoenolpyruvate carboxykinase.136,140
At the same time, glucocorticoids indirectly provide more substrates for gluconeogenesis
via proteolysis in skeletal muscle and lipolysis in adipose tissue.136,141,142 Excess
glucocorticoid production also leads to insulin resistance because translocation of the
GLUT4 glucose transporter to the cell surface is reduced leading to decreased glucose
uptake by muscle and adipose tissue.136,143,144
GR signaling is triggered by a variety of physiological causes.97 Chronic stress
resulting in sustained elevated glucocorticoid exposure throughout a lifetime has negative
physiological consequences.92,94,97,106 Constant GRE binding induces local lasting
changes in DNA methylation shaping subsequent responses to stressors and
glucocorticoids.145-149 It is therefore plausible that chronic stress confers cumulative
effects on DNA methylation sites with long-term epigenetic ramifications.94 Profound
changes in DNA methylation are associated with aging-related diseases.150-156 Because of
this, several DNA methylation-based predictors of aging have been recently
developed.152,157-159 For example, a composite predictor comprised of 353 Cytosinephosphate-Guanosine sites (CpGs) across the genome was shown to strongly correlate
with chronological age across multiple human tissues.152 Several studies have used this
predictor to calculate accelerated epigenetic aging, defined as the difference between
DNA-methylation-predicted age and chronological age.160-163 This accelerated epigenetic
aging has been consequently associated with cancer, obesity, PTSD, physical and
cognitive decline, all-cause mortality, lower SES, and cumulative lifetimes
stress.94,152,161,162 One study found that cumulative lifetime stress was associated with
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accelerated epigenetic aging in AAs.94 This accelerated epigenetic aging was due to
altered GR signaling marked by an increased number of epigenetic clock CpGs located
within functional GREs, dynamic methylation changes following exposure to Dex, and
dynamic regulation by genes with enriched association for aging-related diseases which
neighbored these CpGs.94 These results support a model of stress-induced accelerated
epigenetic aging mediated by the lasting effects of chronic stressor exposure and aberrant
glucocorticoid signaling on the epigenome.94
AAs also appear to have amplified GR signaling and increased glucocorticoid
resistance.164 This was determined by a study exploring the role of body weight and body
composition in insulin resistance and participants were treated with placebo or 4 mg
Dex.164 Results revealed that AAs were significantly more hyperinsulinemic after Dex
treatments than EAs, indicated by higher peak insulin and postprandial insulin.164 AAs
were also found to be more insulin resistant as determined by fasting insulin and
homeostatic model assessment.164 This hyperinsulinemia and increased insulin resistance
in AAs was independent of body weight or composition suggesting that amplified GR
signaling due to hyperactive GRs was more prevalent in the AA study participants.164
Taken together, there is a growing body of evidence that aberrant GR signaling occurs
frequently within the AA population.

Glucocorticoid Signaling and Prostate Cancer
GR is recently emerging as a major driver of PCa progression.134,165-172 A pivotal
study in 2013 identified induction of GR expression as a common feature of ADTresistant PCa tumors using pre-clinical models and confirmed in patient samples.172 Their

22

findings established a mechanism of cellular escape from ADT-induced AR blockade via
GR activating a set of classical AR-target genes thereby maintaining ADT-resistance in
the absence of androgens.172 The implications of this initial finding sparked great interest
as PCa patients are routinely administered synthetic glucocorticoids as co-therapy
alongside ADT and taxane chemotherapy for palliative purposes to reduce adverse side
effects.171,173-175 Furthermore, the mechanism behind the acquisition of ADT-resistance in
PCa cells and the ability to progress in the absence of androgens had previously never
been fully elucidated, and these findings paved the way for others to carefully investigate
the role of GR.171
There are many types of ADT available to PCa patients that employ various
mechanisms of action, and glucocorticoids are co-administered to suppress ACTH
resulting in reduction of adrenal androgenic precursors including dehydroepiandrosterone
(DHEA) (Figure 5).171,176 Complimenting this effect are AR antagonists such as
bicalutamide, flutamide, nilutamide, and Enz.171,177,178 In addition, drugs have been
developed that block the androgen biosynthesis pathway by inhibiting necessary enzymes
such as cytochrome P450 and 17-hydroxylase/17,20-lyase including ketoconazole and
abiraterone.179-182 Taken together, these antiandrogen agents block both androgen
production and action by targeting the HPA and HPT axes as well as PCa intratumoral
androgen synthesis (Figure 5).171
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Figure 5. Mechanisms by which ADT blocks androgen synthesis and action. The HPT
(hypothalamic-pituitary-testicular) axis controls testicular androgen synthesis via
luteinizing hormone (LH). In addition, the HPA regulates androgen precursor synthesis via
ACTH. Once synthesized, testosterone and DHT bind to AR in the prostate. Upon
heterodimerization, AR translocates to the nucleus and interacts with AREs of AR-target
genes. Drugs that reduce androgen synthesis and signaling are used clinically to induce
androgen deprivation in PCa patients. These drugs include GnRH inhibitors that block LH
action, glucocorticoids that inhibit CRH release from the hypothalamus and ACTH from
the pituitary, and ketoconazole and abiraterone that inhibit 17-a-hydroxylase activity
inhibiting adrenal and testicular androgen steroidogenesis. Abiraterone is also able to block
intratumoral synthesis of androgens in PCa cells. In addition, 5-a-reductase inhibitors block
conversion of testosterone to DHT, and AR antagonists such as Enz interfere with
androgen-AR binding thereby blocking AR signaling. (Narayanan S, Srinivas S, and
Feldman D. Nature Reviews Urology. 2016.)
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While ADT is highly effective in producing an initial period of PCa regression,
mCRPC eventually develops characterized by rapidly rising serum PSA levels even
though circulating testosterone levels are in the typical castration range (<50 ng/dl).183-187
This means that AR-target genes are operating in the absence of androgen to stimulate
PCa cell survival, growth, and PSA secretion.171 To understand the prospect of GR
bypassing the AR signaling pathway and directly activating AR-target genes, the
similarities between AR and GR must be dissected. AR and GR belong to the same
intracellular receptor family of transcriptional regulators, and the DNA binding domains
of AR and GR are highly conserved with an 80% match in amino acid sequence.171,188,189
Similar to GREs, AR response elements (AREs) in the promoter regions of AR-target
genes are composed of a 15 base pair binding sequence comprised of two hexamer halfsites and separated by a 3 base pair spacer.190 This similarity allows GR to interact with
ARE and alter the expression of AR-target genes in the absence of androgens.172
These GR-AR interactions in the context of PCa present a major clinical dilemma
because the effects of glucocorticoids are both beneficial and harmful to patients.166168,170-172

Although the natural human glucocorticoid is cortisol (hydrocortisone),

synthetic glucocorticoids prednisone and Dex are routinely used therapeutically.171
Synthetic glucocorticoids have much higher potency than cortisol in activating GR; for
example, 4 mg of prednisone and 0.75 mg of Dex provide the physiological equivalent of
20 mg of cortisol.171 Within the clinic, prednisone is used in doses of 5-10 mg once or
twice per day and Dex is used in doses at 0.75-1 mg once or twice per day.171 When coadministered with taxane chemotherapy for PCa, their potent anti-inflammatory
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properties counteract pain, nausea, lack of appetite, fatigue, hypersensitivity, and fluid
retention.191-195
While the benefits of glucocorticoid co-administration to PCa patients have been
established, there is growing evidence both pre-clinically and in clinical trials that GR
signaling may also be detrimental.134,165-172,196 One study found that GR expression is
initially reduced in primary PCa tissue, but is restored in metastatic lesions.168 This group
also found that GR blockade by RNAi or chemical inhibition impaired the proliferation
and 3D spheroid-forming capabilities of PCa cell lines.168 There is also evidence that GR
is increased in DTX-resistant PCa cell lines and tissue from patients who have been
treated with DTX, and GR antagonists were able to re-sensitize the PCa cells to DTX.169
A separate study reported that patients who relapse with PCa biochemical recurrence and
have high GR, experience shortened progression-free survival.168 Another study
demonstrated that Enz treatment induced GR expression in both PCa cell lines as well as
patient tissue samples.172 Perhaps most disturbing are the reports that PCa patients
enrolled in clinical trials have worse outcome in terms of overall survival when receiving
glucocorticoids compared to patients not receiving glucocorticoids.167,171,197 This trend
was observed in the AFFIRM phase 3 clinical trial evaluating the use of Enz as well as in
the COU-AA-301 phase 3 clinical trial in which patients were randomized to prednisone
plus abiraterone after failing taxane chemotherapy.171,198
The mechanism fueling these adverse outcomes observed in PCa cells and
patients treated with glucocorticoids points toward GR bypass of AR signaling
pathway.172 ADT has been found to elevate PCa cellular GR content leading to activation
of specific AR-target genes by GR, and this activation was achieved by a glucocorticoid-
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GR complex independent of either androgen or AR.172,178 While researchers of that study
identified 52 common overlapping genes out of 105 AR signature genes and 121 GR
signature genes, several canonical AR-target genes were found to be regulated by GR
which included PCa key players KLK3 encoding for PSA and TMPRSS2.172 Also, GR
expression is normally repressed in PCa cells in the presence of AR, however this study
demonstrated that AR blockade removes this GR inhibition and stimulates GR
amplification.172
Whether GR drives ADT-resistance by activating AR-target genes or activating
an independent transcriptome that also drives therapy resistance, the argument is
becoming very clear that GR plays a major role in the progression of mCRPC. There
remains an urgent need however to further elucidate genes driven by GR signaling that
are specifically associated with ADT-resistance while also identifying precise genes that
have been linked to taxane chemotherapy. This is critical to our understanding of
mechanisms by which GR may induce therapy resistance, and the identification of
therapeutic targets.

The Role of LEDGF/p75 in Cancer and Chemoresistance
LEDGF/p75 (also known as PC4 and SFRS1 interacting protein [PSIP1] and
dense fine speckled autoantigen of 70 kD [DFS70]) was initially identified as a growth
factor critical for the proliferation of lens epithelial cells, however subsequent studies
have demonstrated that LEDGF/p75 is activated during the cellular response to stress as a
ubiquitous nuclear transcription co-activator with oncogenic functions.199-202 This protein
has garnered increasing attention due to its relevance to cancer, autoimmunity, eye
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diseases, and HIV-AIDS.201,202 LEDGF/p75 has been firmly established over the last
decade as a critical cellular factor for the integration of the human immunodeficiency
virus 1 (HIV-1) as LEDGF/p75 facilitates this integration of HIV-1 into host integrin
through interaction with the HIV integrase.203-209 LEDGF/p75 specifically promotes
cellular survival against various environmental stressors including oxidative stress,
radiation, heat, serum starvation, and cytotoxic drugs.199-202,210-219 The role of
LEDGF/p75 in PCa is under investigation as it has been shown to contribute to DTXresistance, and also has been shown to be the target of autoantibody responses in a subset
of PCa patients.199,201,220,221
The PSIP gene encodes various splice variants of LEDGF/p75 and has been
mapped to chromosome 9p22.2.200 The most commonly recognized splice variants are
LEDGF/p75 and its shorter variant LEDGF/p52 which are both members of the
hepatoma-derived growth factor (HDGF) family characterized by a highly conserved
proline-tryptophan-tryptophan-proline (PWWP) amino acid sequence motif (Figure
6).201,212,222 The PSIP1/LEDGF gene is made up of 15 exons and 14 introns, with
LEDGF/p75 encoded by exons 1-15 (530 amino acids) and LEDGF/p52 encoded by
exons 1-9 and 24 nucleotides of intron 9 (333 amino acids). Both LEDGF/p75 and
LEDGF/p52 share the amino (N)-terminal residues 1-325 including the PWWP domain.
(residues 1-98) (Figure 6).200,212,222,223 However, the intron-derived carboxyl C-terminal
tail-terminal tail (CTT, amino acid residues 326-333) is present in LEDGF/p52 but is
absent in LEDGF/p75 (Figure 6).224
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There is evidence to suggest the role of the PWWP domain in DNA binding,
transcriptional repression, and methylation.212,222,223,225 When LEDGF/p75 has interacting
proteins bound to its C-terminus, the PWWP domain facilitates the chromatin
recognition, and locking of this protein.226 There is also evidence that LEDGF/p75 binds
to transcriptionally active regions in the chromatin because the PWWP domain
specifically recognizes trimethylated histone H3K36.227 Other important structural
features of the N-terminus of LEDGF/p75 includes three charged domains (CR1, CR2,
CR3), a nuclear localization signal (NLS) (residues 148-156), a TAT-like sequence
within the NLS, and a basic leucine zipper (zip) sequence overlapping with a helix-turnhelix region (residues 154-175) (Figure 6).205,214,228 This zip sequence also overlaps with
two AT-hooks (residues 178-183) which functions as binding to the DNA minor groove
and modifying DNA architecture to facilitate accessibility of promoters to transcription
factors.227 The NLS and AT-hooks within the tripartite region are sufficient for chromatin
binding.228 LEDGF/p75 is able to preferentially bind to active transcription sites in the
negatively supercoiled DNA over unconstrained DNA due to CR2, also referred to as the
supercoiled DNA recognition domain (residues 200-336).229 A non-specific DNArecognition domain also exists in the region comprised of residues 137-206.229
The C-terminus region of LEDGF/p75 (residues 339-442) has been identified as
the HIV integrase binding domain (IBD).205 The IBD entirely overlaps the epitope
recognized by human autoantibodies recognizing LEDGF/p75, and these autoantibodies
have been shown to be produced by healthy individuals as well as patients with different
inflammatory conditions including PCa.201,230 Both the C-terminus and the N-terminus of
LEDGF/p75 are utilized for transcription and stress survival functions via interacting
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with chromatin-binding proteins or binding to specific stress gene promoter
regions.207,231-236 Large random coiled regions containing disordered regions, implicated
in DNA and RNA recognition, modulation of protein binding, and regulation of protein
lifetime are also found in secondary amino acid sequence structures in the C-terminus of
LEDGF/p75.237 A secondary structure consisting of N-terminal b-strand and a-helix was
also predicted by PSIPRED protein structure prediction server V2.1 and PHDsec
programs.212
The interaction of LEDGF/p75 with multiple proteins or DNA to form an
interactivactome suggests its role in multiple cellular processes including proliferation,
growth, differentiation, cell survival, and cell death.201 More specifically, LEDGF/p75
upregulation has been shown to protect against an augmented state of oxidative stress
induced by agents including ultraviolet B irradiation, hydrogen peroxide, alcohol,
hyperthermia, nutrient deprivation, and some chemotherapeutic drugs.211-214,216-219,238-241
Our group reported that, during caspase-dependent cell death, LEDGF/p52 is cleaved by
caspase-3.224 We determined that apoptosis can be induced when LEDGF/p52 or other
splice variants lacking most of the PWWP domain are overexpressed in PCa cell lines.224
In a separate study, we showed that LEDGF/p75 cleavage by caspases-3 and -7 during
apoptosis abrogated its pro-survival functions and accelerated cell death under starvations
conditions.212
LEDGF/p75 is also emerging as a stress oncoprotein driving carcinogenesis when
cells upregulate this protein to evade cell death, induce growth signals, and upregulate
other oncogenic proteins promoting pro-survival functions including cellular repair, DNA
damage protection, lysosomal stability, evasion of proteolysis, and angiogenesis.217,218,242-
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When cells are exposed to damaging agents that induce thermal or oxidative stress,

LEDGF/p75 is upregulated and binds to stress response elements and heat shock
elements in target gene promoter regions.213 As a transcription co-activator, LEDGF/p75
enhances the transactivation of antioxidant genes including albumin, thyroid peroxidase,
superoxide dismutase 3, cytoglobin, and antioxidant protein2/peroxiredoxin 6 to assist
cells in evading cell death through the reduction of oxidative damage.245,246 In addition to
this mechanism of action, LEDGF/p75 enhances the transactivation of HSP27 and crystallin which are anti-apoptotic proteins that respond to stress-related cellular damage
by inhibiting caspase-3 activation.213,247,248 The vascular endothelial growth factor C, a
prosurvival protein involved in angiogenesis and metastasis, is also transactivated by
LEDGF/p75.243,249
Aberrant LEDGF/p75 expression is critical to human leukemogenesis and this
protein was reported as upregulated in chemoresistant blasts obtained from patients with
acute myeloid leukemia (AML).216,250 Several studies have demonstrated that a
chromosomal translocation associated to leukemogenesis, t(9;11)(p22;p15), leads to a
fusion of nucleoporin 98 protein N-terminus to LEDGF/p75 C-terminus.251-257
LEDGF/p75 is also a key co-factor of the mixed lineage leukemia fusion complexes, and
interacts with menin-MLL complexes targeting the homeobox HOX genes associated
with stem cell self-renewal thereby exploiting migrating cancer progenitors.234,257
In terms of PCa, our group previously reported that 22.3% of patients from a
Loma Linda University cohort had circulating serum antibodies that reacted with
LEDGF/p75 compared to 6.7% of normal patient controls.215,220 This finding is consistent
with a separate study from our group demonstrating elevated LEDGF/p75 expression in
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PCa tissues compared to normal adjacent tissue.215,220 Others have also confirmed this
elevated frequency of anti-LEDGF/p75 autoantibodies, contributing to the growing body
of literature suggesting altered LEDGF/p75 expression and function contributes to tumor
aggressive properties.215-220,234,243,248,251-254,258-261 The ability of LEDGF/p75 to serve as a
PCa detection tool has also been explored, and the inclusion of LEDGF/p75 into panels
of tumor-associated antigens for serum autoantibody profiling improved the predictive
frequency in PCa patients compared to PSA blood tests.262,263
The role of LEDGF/p75 in cancer progression, including PCa, is continuing to be
defined and our group was the first to document that elevated LEDGF/p75 protein
expression was detected in clinical PCa tumor and benign prostatic hyperplasia tissues as
compared to their corresponding normal tissues.220 We also reported that LEDGF/p75 is
overexpressed in several human cancers, with statistically significant upregulation of
transcript in prostate, colon, thyroid, and breast cancers, and statistically significant
upregulation of protein in prostate, colon, thyroid, liver, and uterine tumors.215 In addition
to LEDGF/p75 upregulation in cancer malignancies, increased expression of LEDGF/p75
is associated with chemoresistance. One study reported increased LEDGF/p75 transcript
levels in AML blast from chemoresistant patients.216 Increased survival was observed in
AML cells ectopically (plasmid-mediated) overexpressing LEDGF/p75 compared to cells
expressing the empty vector when both cells were treated with daunorubicin or cAMP
analogs, suggesting that increased LEDGF/p75 expression contributes to chemoresistance
in AML.216
Genetic knockdown (siRNAs) of LEDGF/p75 has been shown to result in
increased caspase-independent cell death due to lysosomal membrane permeabilization
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(LMP).218 Conversely, ectopic overexpression of LEDGF/p75 protected MCF-7 cells
against LMP-increasing agents such as siramesine, etoposide, doxorubicin, and TNF but
not against staurosporine which is a classical inducer of apoptosis.218 LEDGF/p75 is also
reported as necessary for effective DNA double strand break repairs.261 Complementing
these studies, our group has explored the link between LEDGF/p75 overexpression and
chemotherapy resistance as it pertains to PCa. We reported that DTX induces a caspaseindependent cell death through lysosomal destabilization and cathepsin B activation in
PCa cells.217 Using PC3 and RWPE-2 PCa cell lines, we found that cells with stable
plasmid-mediated overexpression of LEDGF/p75 were DTX-resistant and exhibited
stable lysosomes compared to cells transfected with an empty vector.217 We speculated
that LEDGF/p75 may protect against lysosomal membrane permeabilization (LMP) but
not against mitotic catastrophe or apoptotic cell death when we also observed that
LEDGF/p75 overexpression did not abrogate DTX inhibition of microtubule
depolymerization or cell death induced by TNF-related apoptosis inducing ligand
(TRAIL).217
In separate studies, we also showed that PCa cells grown in the presence of DTX
and selected for their resistance to this drug, have high endogenous levels of this protein
compared to the parental, drug-sensitive cell lines.199,219,246 More recently, we also
demonstrated that these DTX-resistant cells overexpressing LEDGF/p75 were not only
resistant to DTX, but also exhibited resistance to other taxane drugs used in clinical
settings such as PTX and CTX. While we have demonstrated the role of LEDGF/p75 in
chemoresistance, it has yet to be explored whether this protein is either AR or GR
regulated.
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The Role of Clusterin in Cancer, ADT-Resistance, and Chemoresistance
CLU, also known as testosterone-repressed prostate message, apolipoprotein J,
and sulphated glycoprotein-2, is a secretory heterodimeric disulfide-linked glycoprotein
(449 amino acids) found in all human fluids and widely expressed in many tissues
including brain, ovary, testis, liver, heart, lung, breast, and prostate.264-267 CLU is
involved in a variety of biological processes such as tissue remodeling, lipid transport,
cell-cell interactions, sperm maturation, and apoptosis.268-274 In addition, CLU is also
expressed in many cancers including breast, prostate, ovarian, pancreatic, and renal.275-279
CLU appears to play a particularly important role in PCa as high levels of CLU correlate
with Gleason score and CLU levels increase following both ADT and
chemoresistance.280-282 For this reason, the contribution of CLU to PCa tumor
aggressiveness and therapy resistance continues to be investigated.
Secreted CLU (sCLU) is a glycosylated protein (76-80 kD) and appears as two
different protein bands by immunoblot, one full-length uncleaved 60 kD protein as well
as another 40 kD  and  protein.267,283 sCLU expression is initiated when the first AUG
codon of full-length CLU mRNA is translated into the 49 kD sCLU precursor protein
(Figure 7a).267,283,284 Following translation, a leader signaling sequence directs sCLU to
the endoplasmic reticulum and then transported towards the Golgi where it is cleaved at
the  and  site and heavily glycosylated (Figure 7b).267 The resultant sCLU is 80 kD
consisting of  and  peptides linked together by five disulfide bonds (Figure 7).267 This
form appears at 40 kD by immunoblot.
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Expression of CLU in Malignant Tumours
and its Potential Role as a Prognostic
Marker
Changes in sCLU expression have been documented in a
broad variety of different malignancies including in human
prostate, skin, pancreatic, breast, lung, and colon tumours, as
well as in oesophageal squamous cell carcinoma, and
neuroblastoma.2 It is now accepted that the primary function
of sCLU in distinct genetic backgrounds of cancer cells is
antiapoptotic.2 However, whether increased expression of
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antiapoptotic sCLU is a common feature of tumorigenesis,
thereby protecting cancer cells against apoptotic stimuli that
might cause cell death, is still a matter of debate. Moreover,
the question whether antiapoptotic sCLU is the only form of
CLU expressed in cancer, or whether proapoptotic forms of
nCLU are downregulated in distinct tumour entities (as
discussed above), has not been deﬁnitely answered to date.
Recent data indicate that progression towards high-grade
and metastatic carcinoma leads to elevated sCLU levels and
altered intracellular distribution of nCLU. Thus, the function of
CLU in tumours may be related to a pattern shift in its isoform
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Figure 7. Generation of sCLU and nCLU. (a) sCLU precursor is translated from the first
AUG codon of the full-length CLU mRNA, while nCLU precursor is obtained by
alternative splicing from the second in-frame AUG codon of the full-length CLU mRNA.
Cell extensive
Death and Differentiation
(b) sCLU precursor is transported into the rough ER and undergoes cleavage and
glycosylation while being transported to the Golgi apparatus. This results in sCLU of 80
kD with five disulfide bonds between the  and  subunit that is secreted outside the cell.
nCLU does not undergo cleavage or glycosylation and resides in the cytoplasm of
unstressed cells. It becomes the mature form once it is transported to the nucleus. (Shannan
B et al. Cell Death and Diff 2006.)
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In contrast, nuclear CLU (nCLU) is an initially synthesized protein of 49 kD and
is synthesized from a second in-frame AUG codon resulting from an alternatively spliced
nCLU mRNA; this alternative splicing eliminates exon II and by default the sCLU start
AUG and signaling leader peptide (Figure 7).267 nCLU is localized to the cytoplasm of
normal cells and does not undergo  cleavage or extensive glycosylation (Figure 7b).267
(15) Under conditions of cellular damage, nCLU is post-translationally modified
resulting in a mature 55 kD pro-apoptotic protein that is translocated from the cytoplasm
to the nucleus.267,283 nCLU has been established as pro-apoptotic and capable of
inhibiting cell growth and survival.283,285-288 Conversely, sCLU exerts cytoprotective
properties and tumor cell survival is associated with loss of nCLU and overexpression of
sCLU, and there is evidence that tumor growth is related to a pattern shift in isoform
production.289
Regarding cell death, p53 which is an activator of the apoptotic cascade can
suppress both basal as well as radiation-induced sCLU expression in tumor cells.288 One
study revealed that loss of functional p53 resulted in loss of nCLU function.267 CLU also
appears to be regulated by B-MYB, a transcription factor involved in cell survival,
proliferation, and differentiation.290 CLU has also been found to regulate NF-B which is
also involved in cell survival, motility, proliferation, and transformation.267 The
implications of loss of CLU expression in cells dependent upon NF-B activity for
proliferation or chemoresistance could plausibly lead to tumor progression.267 There is
also evidence that CLU is cell cycle dependent; CLU overexpression in PCa cells led to
increased accumulation of cells at the G0/G1 cell cycle phase resulting in slow down of
cell cycle progression, reduced DNA synthesis, DNA damage accumulation, and
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accelerated PCa progression.291 In addition, CLU appears to play an important role in
DNA repair.292 nCLU protein binds to Ku70 to form a trimeric complex with Ku80
which are two components of the DNA-dependent protein kinase (DNA-PK) complex
involved in nonhomologous DNA double-strand break repair.287,293 CLU overexpression
reduces the binding activity of Ku70/Ku80 to DNA ends.287 Furthermore, nCLU prevents
nonhomologous end joining by releasing Bax from the cytoprotective Ku70-Bax complex
and through inhibition of Ku70/Ku80 end binding activity.267,294
Matrix metalloproteinases (MMPs) are responsible for degradation of most
extracellular matrix components, and MT6-MMP produced by neutrophils is believed to
be important for invasion and migration of cells to inflammatory sites.295 CLU may act as
a MT6-MMP negative regulator demonstrating an important role for this protein in cell
matrix formation, cell membrane remodeling, and morphological tissue modulation.267 In
a study overexpressing CLU (plasmid-mediated) in a PCa cell line, membrane damage
was inhibited in the presence of hydrogen peroxide compared to cells transfected with
empty vector.296
Progression of PCa to castration-resistance requires an upregulation of antiapoptotic genes following ADT, and CLU expression has been linked to ADT-resistance
for over a decade.282 There is also evidence that PCa cell transformation at early stages
requires CLU silencing through chromatin remodeling.297 An early study observed a 17fold increase in CLU expression in malignant tissue from PCa patients who underwent
ADT compared to untreated patients implying that CLU is upregulated in cells as an
adaptive cell survival response.282 Several others have employed a variety of molecular
techniques to elucidate the mechanism by which this CLU upregulation occurs in PCa
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cells. Using the PC3 cell line, researchers found that co-treatment with siRNA targeting
CLU in combination with paclitaxel significantly enhanced the cytotoxic effect of
paclitaxel.298 In a separate study, both transcript and protein of CLU increased with
androgen treatment in a time- and dose-dependent manner, and AR antagonist
bicalutamide inhibited this increase in CLU.299 The first intron of the CLU gene contains
putative AREs and was confirmed by chromatin immunoprecipitation and reporter assays
to be both bound by AR and transactivated.299 When PCa cells were treated with Enz,
CLU protein levels significantly increased as Enz-resistance developed; and CLU
knockdown enhanced the cell growth inhibitory effects of Enz.300 This increase in CLU
was also observed in a dose- and sequence-dependent manner when AR was specifically
targeted with AR antisense in PCa cells.300 A combination of Enz plus CLU silencing
was able to significantly reduce AR nuclear translocation and transcriptional activity of
AR as well as accelerated proteasome-mediated AR degradation.300
In addition to CLU’s role in ADT-resistance, CLU has been shown to be
instrumental in the acquisition and maintenance of chemoresistance.280,281 The gold
standard treatment for PCa is taxane chemotherapy, namely DTX, and CTX, and these
agents induce cell death by stabilizing microtubules resulting in mitotic catastrophe.301
Taxanes are also highly effective in disrupting bcl-2 phosphorylation thereby reversing
its anti-apoptotic function.302,303 However, the beneficial effects of taxane chemotherapy
are short-lived and eventually PCa patients develop chemoresistance, and CLU plays a
major role.280,281 There is evidence that CLU overexpression helps to create a
chemoresistant phenotype.280 For example, LNCAP PCa cells are highly sensitive to
taxane paclitaxel, but when transfected with CLU, LNCAP cells were able to withstand
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paclitaxel and avoid apoptotic cell death.280 Similar studies using PC3 cells demonstrated
that CLU blockade with specific siRNA re-sensitized cells to paclitaxel.284,304 In vivo
studies in nude mice reported that parental human LNCAP tumors quickly regressed
following castration and paclitaxel treatment, but CLU overexpressing LNCAP continued
to grow.280 A complementary study was performed using Shionogi tumors characterized
as CLU-positive; CLU antisense used in conjunction with paclitaxel was highly effective
in tumor shrinkage.280 Similar studies have also been conducted in renal carcinoma,
breast, and lung cancer pre-clinical cellular models and the results have mirrored what
has been described in PCa cells.305-307 Given that CLU confers survival advantage to
cancer cells and is easily induced by therapeutic agents, CLU targeting remains under
investigation as a plausible clinical option to overcome drug resistance.280 Because of
these findings at the benchside, clinical trials were recently developed to co-target CLU
in combination with ADT or taxane chemotherapy for PCa patients.175,308
While CLU has been established as a driver of ADT-resistance and
chemoresistance in PCa cells and patient samples, the potential regulation of CLU by GR
in the absence of AR function has yet to be explored.
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CHAPTER TWO
THE 22RV1 PROSTATE CANCER CELL LINE CARRIES MIXED GENETIC
ANCESTRY: IMPLICATIONS FOR PROSTATE CANCER HEALTH
DISPARITIES RESEARCH USING PRE-CLINICAL MODELS

Abstract
Understanding how biological factors contribute to prostate cancer (PCa) health
disparities requires mechanistic functional analysis of specific genes or pathways in preclinical cellular and animal models of this malignancy. The 22Rv1 human prostatic
carcinoma cell line was originally derived from the parental CWR22R cell line.
Although 22Rv1 has been well characterized and used in numerous mechanistic studies,
no racial identifier has ever been disclosed for this cell line. In accordance with the need
for racial diversity in cancer biospecimens and recent guidelines by the NIH on
authentication of key biological resources, we sought to determine the ancestry of 22RV1
and authenticate previously reported racial identifications for four other PCa cell lines.
We used 29 established Ancestry Informative Marker (AIM) single nucleotide
polymorphisms (SNPs) to conduct DNA ancestry analysis and assign ancestral
proportions to a panel of five PCa cell lines that included 22Rv1, PC3, DU145, MDAPCa-2b, and RC-77T/E. We found that 22Rv1 carries mixed genetic ancestry. The main
ancestry proportions for this cell line were 0.41 West African (AFR) and 0.42 European
(EUR). In addition, we verified the previously reported racial identifications for PC3
(0.73 EUR), DU145 (0.63 EUR), MDA-PCa-2b (0.73 AFR), and RC-77T/E (0.74 AFR)
cell lines. Considering the mortality disparities associated with PCa, which
disproportionately affect African American men, there remains a burden on the scientific
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community to diversify the availability of biospecimens, including cell lines, for
mechanistic studies on potential biological mediators of these disparities. This study is
beneficial by identifying another PCa cell line that carries substantial AFR ancestry. This
finding may also open the door to new perspectives on previously published studies using
this cell line.

Introduction
African American (AA) men and other men of African ancestry have the highest
incidence and mortality rates of prostate cancer (PCa) in the world, resulting in the
highest reported cancer health disparity. We use the term “African American”
recognizing that while race is a social construct, racial classification remains extremely
useful for describing general patterns of national health and health disparities, as most
U.S. health data are reported by self-identified race.1-5 Recent studies have provided
compelling evidence in support of the notion that PCa health disparities result from the
interplay of multiple factors, including biological/genetic factors.6-8 For instance, several
recent studies have reported genomic differences between AA men with PCa and
Caucasian or European American (EA) with PCa, suggesting a potential role for
biological mediators in driving PCa mortality disparities. 9-13 Understanding how these
mediators contribute to increased PCa mortality in AA men requires mechanistic
functional studies in pre-clinical cellular and animal models of PCa.
Given the inherent difficulties in conducting mechanistic studies in primary PCa
cells, including transfection issues and high degree of molecular variability as these
primary cells propagate in vitro,14-16 it is essential to have available a well-characterized,
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racially diverse, patient-derived cohort of immortalized cell lines representing different
stages of PCa. Unfortunately, there is currently a lack of racial diversity in the human
PCa cell lines that are commercially available for research. While there is over a dozen of
commercially available human prostate cell lines of European ancestry that are
representative of various prostate phenotypes such as normal and different PCa stages,
there are only three cell lines identified as having African ancestry (Table 1).17-29 This
limits the scope of in vitro studies addressing mechanistic events involving potential
biological factors associated with PCa health disparities.
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Table 1. Commonly Used Commercially Available Prostate Cell Lines
Cell Line

Site of Origin

Race/ Ethnicity

Source

Reference

22Rv1

Primary xenograft

Not Available

ATCC

Sramkoski RM et al. 1999

DU145

Brain metastasis

EA/ White

ATCC

E006AA-hT

Primary tumor

AA/ Black

ATCC

Stone KR et al. 1978
Koochekpour S et al. 2014

LAPC-3

Not Available

ATCC

Klein KA et al. 1997

Not Available

ATCC

Klein KA et al. 1997

EA/ White

ATCC

Horoscewicz JS et al. 1983

MDA-PCa-2a

Prostate xenograft
Lymph node
metastasis
Lymph node
metastasis
Bone metastasis

AA/ Black

ATCC

Navone NM et al. 1997

MDA-PCa-2b

Bone metastasis

AA/ Black

ATCC

Navone NM et al. 1997

PC3

EA/ White

ATCC

Kaighn ME et al. 1979

Variable

Lonza

Not applicable

RWPE-1

Bone metastasis
Normal human
primary prostate
epithelial cells
Normal
prostate/stroma
Normal prostate
Normal
prostate/epithelial
Normal prostate

RWPE2
RWPE2-W99

LAPC-4
LNCaP

PrEC
PrSC/WPMY-1
PWR-1E
PZ-HPV-7

VCaP

WISH-PC2
WPE1-NA22
WPE1-NB11
WPE1-NB14
WPE1-NB26

EA/ White

ATCC,
Lonza
ATCC

EA/ White

ATCC

Weijerman PC, et al. 1994

EA/ White

ATCC

Bello D et al. 1997

Normal prostate

EA/ White

ATCC

Bello D et al. 1997

Normal prostate
Vertebral
metastasis
Neuroendocrine
xenograft prostate
small-cell
carcinoma
Prostate

EA/ White

ATCC

Bello D et al. 1997

EA/ White

ATCC

Loberg RD et al. 2006

ATCC

Pinthus JH et al. 2008

EA/ White

ATCC

Webber MM et al. 2001

Normal prostate
Normal
prostate/epithelial

EA/ White

ATCC

Webber MM et al. 2001

EA/ White

ATCC

Bello D et al. 1997

Normal prostate

EA/ White

ATCC

Webber MM et al. 2001

EA/ White

EA/ White

Webber MM et al. 1999
Webber MM et al. 1996

AA, African American; ATCC, American Type Culture Collection; EA, European American
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Research into molecular and genetic mechanisms underlying PCa mortality
disparities will be greatly advanced by the availability of pre-clinical cellular models of
AA prostate tumors representing different stages of the disease.30 There is a growing
awareness of the need for biospecimens from AA populations that could be used for
biomedical research, and an effort has been made by PCa researchers to develop AA
prostate cell lines for cancer health disparities research.30-33 For example, RC-77N/E and
RC-77T/E is a pair of African American prostate cell lines that were recently developed
by one of the co-authors in this study (CY), and are available for research upon request.30
While we recognize that the use of cell lines in cancer research has limitations, and that
determinants of PCa health disparities may not be conclusively identified via in vitro
studies, the use of racially diverse PCa cell lines in mechanistic studies may provide
important clues into contributing biological mediators.
The 22Rv1 human prostatic carcinoma cell line was derived from a xenograft of
CWR22R cells serially propagated in mice after castration-induced regression.17,34 A
number of biological characteristics were specified when 22Rv1 was derived, including
epithelial lineage, DNA content, and cytogenetic data.17 The donor patient clinical
information provided for the parental cell line CWR22R was the diagnosis of Stage D
primary prostatic carcinoma with Gleason score of 9 advanced to osseous metastasis.34
While conducting studies using 22Rv1 cells we noticed that no racial identifier was ever
released for this cell line or the parental CWR22R, and no subsequent DNA ancestry
analysis has been conducted to identify its ethnicity.17,34 Recently, the National Institutes
of Health established guidelines concerning the authentication of key biological
resources, including cell lines, in order to ensure the identity and validity of the resource.
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This authentication applies to racial identity if the cell line is being used in biological
studies relevant to cancer health disparities. In this context, we sought to determine the
ancestry of 22Rv1 and authenticate, using genetic ancestry analysis, a few previously
racially identified cell lines used in PCa research. These included the PCa cell lines
MDA-PCa-2b and RC-77T/E, previously reported as Black or AA,22,30 and the PC3 and
DU145 cell lines, previously reported as Caucasian or EA.18,23
30

To determine the ancestry of the 22Rv1 cell line we used a set of Ancestry

Informative Markers (AIMs) validated as single nucleotide polymorphism (SNP)
genotypes for population structure analyses.35 PC3, DU145, MDA-PCa-2b, and RC77T/E cell lines were included in the study to further validate their previously reported
ethnicities and serve as controls for our SNP genotypes.18,22,23 Our analysis confirmed
predominant European (EUR) ancestry in PC3 and DU145 cells as well as predominant
West African (AFR) genetic ancestry in the MDA-PCa-2b and RC-77T/E cells.
However, the 22Rv1 cell line was found to carry substantial AFR genetic ancestry. The
racial classification of 22Rv1 as a mixed ancestry cell line with substantial AFR genetic
ancestry expands diversity within the existing pool of human PCa cell lines. This finding
may offer a new perspective on previously published studies using this cell line.

Materials and Methods
Cell Culture
Cell lines were purchased from American Type Culture Collection (ATCC) and
grown in a humidified incubator with 5% CO2 at 37oC. Cells were routinely tested for
mycoplasma contamination using MycoAlert PLUS Mycoplasma Detection Kit (Lonza,
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Cat. # LT07). PC3 (ATCC, Cat. # CRL-1435), DU145 (ATCC, Cat. # HTB-81), and
22Rv1 (ATCC, Cat. # CRL-2505) cell lines were cultured in RPMI 1640 medium
(Corning, Cat. # 10-040-CV) supplemented with 10% fetal bovine serum (Corning, Cat. #
35010CV), penicillin-streptomycin (Corning, Cat. # 30001Cl), and gentamicin (Gibco,
Cat. # 15710064) as recommended by the supplier. MDA-PCa-2b (ATCC, Cat. # CRL2422) cell line was cultured in F-12K medium (ATCC, Cat. # 30-2004) supplemented
with 20% fetal bovine serum (Corning, Cat. # 35010CV), cholera toxin (Sigma-Aldrich,
Cat. # C8052), epidermal growth factor (Sigma-Aldrich, Cat. # E4127), ophosphoethanolamine (Sigma-Aldrich, Cat. # P0503), hydrocortisone (Sigma-Aldrich,
Cat. # H0888), selenious acid (ACROS Organics, Cat. # AC19887), bovine insulin
(Sigma-Aldrich, Cat. # I6634), and penicillin-streptomycin as recommended by the
supplier. 0.2% Normocin (Invivogen, Cat. # ANT-NR-1) was added to the medium for
PC3, DU145, 22Rv1, and MDA-PCa-2b cell lines to prevent contamination by
mycoplasma, bacteria, or fungi. The RC-77T/E cell line was cultured with keratinocyte
serum-free medium (K-SFM) with L-glutamine supplemented with bovine pituitary
extract and recombinant epidermal growth factor 1-53 (Life Technologies, Cat. # 17-005042). Fungizone (0.4%, Gibco, Cat. # 15290018) was added to this medium to prevent
contamination by yeast or multicellular fungi. To ensure proper cell attachment to
culture plates, RC-77T/E cell line was cultured in 1% collagen-treated dishes (100mm x
20mm) (Life Technologies, Cat. # A1064401).
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DNA Extraction
DNA was extracted using the QIAamp DNA mini kit (Qiagen, Valencia, CA, Cat.
# 51104) following the manufacturer’s protocol. Briefly, cells were grown in a monolayer
at confluency no greater than 5x106. Medium was aspirated and cells were washed with
Dulbecco’s phosphate-buffered saline (PBS) (Corning, Cat. # 21030CM) and then
trypsinized with 0.25% trypsin (Corning, Cat. # 25-053-Cl) to detach them from the
culture flask. Cells were then collected in appropriate medium, transferred to a 1.5 ml
microcentrifuge tube, and centrifuged for 5 minutes at 300 x g. Supernatant was removed
and cell pellet was resuspended in PBS to a final volume of 200 l. After this, 20 µl
Proteinase K and 200 µl of Qiagen buffer AL were added and the sample was incubated
for 10 min at 56°C. Then, 200 µl of ethanol was added, and DNA was purified using the
columns provided in the kit according to the manufacturer's instructions. The samples
yielded approximately 6 g of DNA with an A260/A280 ratio of 1.7-1.9. The samples were
diluted in distilled water and stored at -20°C. Samples were shipped to the UCLA
Sequencing and Genotyping Core, Department of Human Genetics, David Geffen School
of Medicine, University of California, Los Angeles for subsequent SNP genotyping.

Selection of Ancestry Informative Marker (AIM) SNPs
We used 29 Ancestry Informative Marker (AIM) SNPs validated in a previous
study involving determination of admixture proportions in human continental
populations.35 We selected the smallest subset of 24 AIMs and 5 additional SNPs from
the previous study, as a cost-and time-effective strategy, to determine the ancestry of the
above-mentioned PCa cell lines of interest. All the 29 selected SNPs exhibited large
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allele frequency differences between four continental populations- AFR, EUR, AmeriIndian (AMI), and East Asian (EAS) in the previous study.35 We confirmed the allele
frequency differences between these ancestral groups for each of the 29 AIM SNPs using
the NCBI dbSNP database.

SNP Genotyping
SNP genotyping was done using the Fluidigm Biomark HD system (South San
Francisco, CA) at the UCLA Genotyping core facility. SNPtype™ assays and reagents
for each of the SNPs were purchased from Fluidigm. DNA samples and assays were
loaded onto GT 96*96 Dynamic array and processed per Fluidigm protocol. The
genotyping calls were made using Fluidigm SNP genotyping software. Each DNA
sample was analyzed in triplicate to ensure accuracy.

DNA Ancestry Analysis
Data for the current study was analyzed as part of a larger project involving 1078
DNA samples. Markers showing different alleles at very high frequency in distinct
putative parental populations were used to efficiently distinguish different populations
and for the inference of ancestry membership proportions. In this study, we used 29
selected unlinked AIM SNPs as 29 loci for the STRUCTURE software version 2.3.4, for
providing an estimation of genetic ancestry. Allele frequencies for the 29 AIM SNPs are
provided in Table 2. The software was installed and run locally after importing the SNP
data for 1078 DNA samples in the form of a matrix where the data for samples were in
rows and the loci were in columns (.txt file). For the determination of true K or the

76

assumed number of populations, length of the Burnin period used was 5,000, the number
of Markov Chain Monte Carlo (MCMC) replicates after the Burnins was 50,000 and K
was set for 1-10 with 3 replicates for each K. True K was determined to be equal to 2~3
by L(K) (log likelihood of each K) method, using Structure Harvester with a zipped
version of the results from STRUCTURE, as an input file. After the determination of true
K, STRUCTURE was run three times, without any prior population assignment for an
admixture population using 100,000 as the length of the Burnin period and 500,000 as the
number of MCMC replicates after the burnins, for K=2 and K=3. The missing value was
represented as -9, the maximum value of ALPHA (ALPHAMAX) was 10.0 and the SD
of proposal for updating ALPHA was 0.025, while rest of the parameters used were
default. The three clusters obtained as an output from STRUCTURE were assigned EUR,
AFR, and AMI ancestries by crosschecking the allele frequencies for AIMs of multiple
DNA samples within each cluster against those found in NCBI dbSNP. The bar plot was
generated by STRUCTURE for visualization of ancestral proportions in each sample.
PC3 and DU145 cells along with MDA-PCa-2b and RC-77T/E cells served as controls
for EUR and AFR ancestries, respectively, and aligned well with the results where K=3.
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Table 2. Validated Ancestry Informative Marker Single Nucleotide Polymorphisms to
Determine Ancestry Assignment of Prostate Cancer Cell Lines
dbSNP ID

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

rs4891825
rs9530435
rs1040045
rs7554936
rs772262
rs3784230
rs260690
rs10007810
rs7657799
rs6548616
rs4908343
rs11652805
rs9522149
rs10108270
rs6451722
rs9319336
rs870347
rs7803075
rs2416791
rs6422347
rs7997709
rs 731257
rs 4918842
rs10496971
rs12629908
rs3907047
rs1513181
rs1471939
rs2125345

Chromosome
Number

Nucleotide
Change

18
13
6
1
12
14
2
4
4
3
1
17
13
8
5
13
5
7
12
5
13
7
10
2
3
20
3
8
17

G/A
T/C
T/C
T/C
G/A
T/C
C/A
G/A
T/G
T/C
G/A
T/C
T/C
C/A
G/A
T/C
T/G
G/A
G/A
G/A
T/C
G/A
T/C
T/G
G/A
C/T
C/T
C/T
A/G

Allele 1 frequency
EUR
0.89
0.79
0.73
0.34
0.06
0.58
0.91
0.25
0.05
0.25
0.82
0.14
0.76
0.35
0.24
0.05
0.95
0.29
0.08
0.10
0.06
0.09
0.15
0.09
0.05
0.06
0.14
0.17
0.32

AFR
0.09
0.07
0.10
0.99
0.87
0.00
0.36
0.96
0.86
0.96
0.04
0.98
0.03
0.97
0.90
0.11
0.95
1.00
0.94
0.89
0.23
0.02
0.09
0.06
0.16
0.00
0.21
0.32
0.99

dbSNP, NCBI Single Nucleotide Polymorphism database; EUR, European; AFR, West African
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Results
Informative Ancestry Markers for Distinguishing Ancestral Proportions
An initial subset of 24 AIM SNPs was selected from a validated larger set of 128
SNPs previously identified to define critical genome candidate regions and used to
characterize samples from diverse population groups (Table 2).35 This subset of 24 AIMs
contained specific SNPs capable of distinguishing the following four continent
populations: EUR, AFR, AMI, and EAS.35 Five additional AIMs from the validated
larger set of 128 AIMs were added to the smaller subset of 24 AIMs, bringing our total
quantity of AIMs used for DNA ancestry analysis to 29 (Table 2).

Determination of Ancestral Proportions of Prostate Cancer Cell Lines
Each PCa cell line analyzed in our study possessed heterogeneous ancestral
proportions (Figure 8, Table 3). However, for each cell line where ATCC provided a
racial classification, we observed a predominant ancestral proportion that was consistent
with what was previously reported. For instance, PC3 and DU145 cell line samples were
included in our analysis as EUR controls, and MDA-PCa-2b and RC-77T/E as AFR
controls based on their previously reported racial classification.18,22,23,30 PC3 is classified
by ATCC as Caucasian and was found to carry 0.73 proportion of EUR ancestry. This
cell line was also found to carry 0.19 AFR and 0.08 AMI ancestral proportions. DU145 is
also classified by ATCC as Caucasian and was found to carry 0.63 proportion of EUR
ancestry. Interestingly, DU145 was also found to carry 0.28 AFR and 0.09 AMI ancestral
proportions. MDA-PCa-2b is classified by ATCC as Black and was found to carry 0.73
proportion of AFR ancestry as well as 0.13 AMI and 0.14 EUR ancestral proportions.
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RC-77T/E is not available through ATCC, however it was reported by one of the authors
of this study (C. Yates) as an AA cell line,30 and our results confirmed this. RC-77T/E
was found to carry 0.74 proportion of AFR ancestry as well as 0.09 AMI and 0.17 EUR
ancestral proportions. To date, there has never been a racial classification assigned to
22Rv1. Our results indicated the following ancestral proportions for 22Rv1: 0.41 AFR,
0.17 AMI, and 0.42 EUR. Therefore, 22Rv1 should be considered as a mixed ancestry
cell line.
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Figure 8. DNA Ancestry Analysis Reveals Ancestral Proportions of Prostate Cancer Cell
Lines. DNA was isolated and extracted from five PCa cell lines and submitted to the
UCLA genomics core for SNP genotyping. Cell lines included EUR controls PC3 and
DU145, AFR controls MDA-PCa-2b and RC-77T/E, and the racially ambiguous 22Rv1.
DNA samples were analyzed in triplicate to ensure accuracy. The bar plot shown in this
figure was generated using STRUCTURE for visualization of the ancestral proportion in
each sample. Subsequent analysis of population substructure was also conducted using
STRUCTURE, a model-based clustering software able to detect the underlying genetic
population among a set of individuals genotyped at multiple markers with the help of a
bayesian approach. Using STRUCTURE, we were able to compute the proportion of the
genome of the cell lines originating from each inferred population. Blue: AFR ancestry;
Green: AMI ancestry; Red: EUR ancestry.
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Table 3. Ancestry Proportions in Panel of Prostate Cancer Cell Lines
Cell Line
PC3
DU145
MDA-PCa-2b
RC-77T/E
22Rv1

Proportion of Ancestry
AFR
0.19
0.28
0.73
0.74
0.41

AMI
0.08
0.09
0.13
0.09
0.17

Samples were analyzed in triplicates to ensure accuracy.
AFR, African ancestry; AMI, Ameri-Indian ancestry; EUR, European ancestry.
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EUR
0.73
0.63
0.14
0.17
0.42

Discussion
In concordance with recent NIH guidelines requiring authentication of cell lines,
this study sought to determine the racial identity of 22Rv1 PCa cells since racial
classification/ethnicity for this cell line has never been reported to ATCC or previously
published.17,34 It has been our experience in personal communication with other groups
that that 22Rv1 is widely considered as a EA PCa cell line, and we had no reason to
explore this assumption until we began incorporating various EA and AA cell lines in our
studies.36-38 We initially conducted a thorough literature search and contacted ATCC to
determine if there was any indication of racial identification for either 22Rv1 or its
parental cell line CWR22R. In addition, we communicated with key authors of the initial
reports on the characterization of both cell lines to determine if there was any racial
identification linked to the tumor biospecimen from which these cell lines were
derived.17,34 Unfortunately, these efforts did not provide any indication as to the racial
classification of these cell lines. This lack of information prompted us to conduct DNA
ancestry analysis on 22Rv1 cells and provide this information to the PCa research
community and the scientific community at large. We felt this was a very important issue
given the need for a comprehensive panel of racially diverse patient-derived cell lines for
mechanistic studies on potential biological mediators of PCa mortality disparities.
SNP genotyping and subsequent DNA ancestry analysis were chosen as
appropriate methods to determine the ancestry for 22Rv1. Other investigators have
shown that differences in allele frequencies can be used to identify continental population
groups.39,40 This is because several studies have demonstrated that large differences in
allele frequencies between two or more continental populations can be attributed to many
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individual SNPs distributed throughout the genome.41-44 In this study, 29 AIM SNPs were
chosen from a validated larger set of 128 SNPs previously identified by others to define
critical genome candidate regions and used to characterize samples from diverse
population groups.35 Differences in population structure were addressed by extending
genetic associations to minority groups that include extensive admixture between
continents.35 This genetic association extension was essential to evaluate ethnic
disparities in disease risk among multiethnic and admixed populations as a large number
of whole genome association studies have evaluated populations of predominantly EUR
ancestry.35
Our analysis revealed that the 22Rv1 PCa cell line carries AFR genetic ancestry,
with almost equal proportions for AFR and EUR ancestry (41% and 42%, respectively).
While this study authenticates the previously reported racial identification of several PCa
cell lines (PC3, DU145, MDA-PC-2b, and RC-77T/E), it establishes for the first time the
ancestral composition of 22Rv1. Because 22Rv1 was derived from a xenograft of
CWR22R which was serially propagated in mice,17,34 it would be appropriate to also
assign this mixed ancestral racial classification to CWR22R. The implications of 22Rv1
and CWR22R carrying AFR genetic ancestry are far reaching as genetic factors
associated with AFR ancestry have been recently linked to prostate tumor aggressive
properties.9-13,45-47 Further studies are needed to determine if these cell lines carry any of
these factors. In addition, our findings open the door for closely examining previous
studies using 22Rv1 and CWR22R cells under the new perspective that these cell lines
carry almost equal proportions of AFR and EUR genetic ancestry.
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We suggest that 22Rv1 and CWR22R can be added to the current roster of PCa
cell lines that are classified as Black, AA, or carry substantial AFR genetic ancestry,
including MDA-PCa-2b, RC-77N/E, and RC-77T/E.19,22,30 Alternatively, they could be
classified in a separate category as racially mixed ancestry cell lines. We cannot rule out
the possibility that CWR22R was originally derived from a Hispanic male of Caribbean
heritage as the proportions of AFR, AMI, and EUR genetic ancestry found in the 22RV1
cell line are common in men from this geographical region.48-50 For example, recent
studies have highlighted the high tri-hybrid admixture (Native American, European, West
African) of the Puerto Rican population.48,49 Knowledge that 22Rv1 carries substantial
AFR ancestry would be beneficial to efforts to expand the selection of racially diverse
cell lines for in vitro mechanistic studies focusing on potential determinants PCa
mortality disparities that could be attributable to genetically- and racially-driven tumor
biological differences. It is important to note that while this study contributes to the
increasing diversity of PCa cell lines, thus far all available AA PCa cell lines are derived
from patients with metastatic disease and tumors with functional androgen and
glucocorticoid receptors. There remains a critical need for AA PCa cell lines derived
from metastatic androgen-independent tumors (e.g. equivalent to the EA PC3 and
DU145). This would be important for mechanistic studies on different disease stages
using AA PCa cell lines.

Conclusions
The field of PCa health disparities research continues to advance, with recent
attention to potential biological determinants or mediators of these disparities that could
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be mechanistically examined using a panel of racially diverse, patient-derived cell lines.
The identification of 22Rv1 as a mixed ancestry PCa cell line carrying substantial AFR
genetic ancestry provides an additional resource to advance molecular/cellular research in
the context of PCa health disparities. While there still remains a deficit in the availability
of AA PCa cell lines and clinical biospecimens, the trend towards acquiring additional
specimens appears to be growing.31-33 The knowledge to be gained from mechanistic
studies incorporating biospecimens (cell lines plus tumor samples) from AA men will not
only have the potential to reduce the mortality disparities associated with this malignancy
but also benefit the field of PCa research in general.
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CHAPTER THREE
GLUCOCORTICOIDS INDUCE STRESS ONCOPROTEINS ASSOCIATED
WITH THERAPY-RESISTANCE IN AFRICAN AMERICAN AND EUROPEAN
AMERICAN PROSTATE CANCER CELLS

Abstract
Glucocorticoid receptor (GR) is emerging as a key driver of prostate cancer (PCa)
progression and therapy resistance in the absence of androgen receptor (AR) signaling.
Acting as a bypass mechanism, GR activates AR-regulated genes, although GR-target
genes contributing to PCa therapy resistance remain to be identified. Emerging evidence
also shows that African American (AA) men, who disproportionately develop aggressive
PCa, have hypersensitive GR signaling linked to cumulative stressful life events. Using
racially diverse PCa cell lines—MDA-PCa-2b, 22Rv1, PC3, and DU145—we examined
the effects of glucocorticoids on the expression of two stress oncoproteins associated with
PCa therapy-resistance, Clusterin (CLU) and Lens Epithelium-Derived Growth Factor
p75 (LEDGF/p75). We observed that glucocorticoids upregulated LEDGF/p75 and CLU
in PCa cells, most robustly in cell lines of substantial African ancestry, MDA-PCa-2b and
22Rv1. Blockade of GR activation abolished this upregulation. We also detected
increased GR transcript expression in AA PCa tissues, compared to European American
(EA) tissues, using Oncomine microarray datasets. These results demonstrate that
glucocorticoids upregulate the therapy resistance-associated oncoproteins LEDGF/p75
and CLU, and suggest that this effect may be enhanced in AA PCa. This study provides
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an initial framework for understanding the contribution of glucocorticoid signaling to
PCa health disparities.

Introduction
For decades, androgen deprivation therapy (ADT) has been a mainstay of
treatment for advanced prostate cancer (PCa).1-3 The mechanism of action of ADT
involves the lowering of serum testosterone or competitively blocking the binding of
androgens to androgen receptor (AR). However, this therapy is not curative, as several
studies have conclusively demonstrated that prostate tumors develop ADT-resistance .1,2
Glucocorticoid receptor (GR) signaling has recently been shown to drive ADT-resistance
via its ability to bypass the AR pathway blockade and directly restore activation of ARtarget genes in addition to activating an independent transcriptome that also drives
therapy resistance.1,4-9
A pressing implication is that glucocorticoid therapy presently administered to
PCa patients as a standard of care could be detrimental under certain clinical
conditions.1,9-11 For example, there is evidence that glucocorticoids promote PCa
progression in patients whose tumors express GR, and that men who receive
glucocorticoids concomitantly with the second-line ADT drug enzalutamide have
significantly worse survival.4,6 However, a clinical dilemma exists as glucocorticoids
confer many palliative benefits to patients who often suffer from debilitating side effects
of their treatment.12
Similarly, the importance of glucocorticoid co-therapy also extends to taxanebased chemotherapeutic regimens for patients with metastatic castration-resistant PCa
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(mCRPC). The taxane drugs docetaxel (DTX) and cabazitaxel (CTX) can extend patient
survival, however, they are also not curative because patients eventually develop
resistance to these drugs.13,14 Glucocorticoids are commonly co-administered with
taxanes to mitigate side effects of chemotherapy such as nausea, vomiting, and
inflammatory reactions. Of concern, however, is the recent evidence pointing to the
possible contribution of GR signaling to the acquisition of taxane resistance in breast and
prostate cancers.15,16 These recent studies indicated that simultaneous exposure of the
cancer cells to DTX and the clinically relevant glucocorticoid dexamethasone (Dex) led
to increased resistance to DTX.
While the ability of GR to activate AR-target genes in the context of mCRPC has
been demonstrated,1,4-11 there is a need to identify specific genes driven by GR signaling
that have been previously linked to taxane chemotherapy. This is critical to our
understanding of mechanisms by which GR may induce taxane resistance, and the
identification of potential therapeutic targets. We hypothesized that stress oncoproteins
that are upregulated in the context of standard PCa treatments and that promote therapy
resistance may be upregulated by GR signaling. As a first step in evaluating this
hypothesis we focused on the contribution of GR signaling to the expression of the stress
oncoproteins Clusterin (CLU) and Lens Epithelium-Derived Growth Factor p75
(LEDGF/p75), previously shown to be upregulated in response to standard PCa therapies,
including taxane therapy.17-26 CLU is an AR-regulated, anti-apoptotic protein that is
upregulated in PCa, particularly following ADT, as well as several other
cancers.18,20,22,27,28 CLU has two isoforms that result from two transcriptional start sites;
nuclear CLU is pro-apoptotic and sequestered in the nucleus whereas secreted CLU
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(sCLU) is ultimately secreted following post-translational modifications and cleavage
into two distinct alpha and beta peptides held together by disulfide bonds.18,19,29 Before
cleavage, sCLU exists in the cytoplasm as a pre-secreted form (psCLU) and both forms
contribute to DTX resistance.19,21
Similar to CLU, LEDGF/p75 also promotes taxane resistance in PCa cells, albeit
by a different mechanism. Our group and others have demonstrated that LEDGF/p75 is a
stress response transcription co-activator upregulated in PCa as well as other cancers that
promotes cellular survival in the presence of chemotherapeutic drugs.25,26,30-34 While
CLU inhibits drug-induced apoptosis by preventing mitochondrial membrane
permeabilization,19,21,22 LEDGF/p75, acting as a stress transcription co-activator,
transactivates stress response and anti-oxidant genes, and promotes resistance to
oxidative stress-induced necrosis and DTX-induced caspase-independent lysosomal cell
death.25,26,30,31 In a recent study, we showed that depletion of LEDGF/p75 in DTXresistant mCRPC cells partially resensitized the cells to DTX treatment.26 In addition,
other groups have shown that downregulation of LEDGF/p75 reduced cancer cell
proliferation, migration, tumorigenicity, and sensitized cancer cells to anti-tumor drugs.3538

The implications of glucocorticoid-activated GR signaling upregulating
oncoproteins associated with tumor progression and therapy resistance are far-reaching
and have the potential to impact PCa patients who may have elevated levels of
endogenous cortisol or a propensity for hypersensitive GR signaling. For example,
individuals exposed to chronic stressful life events tend to have increased cortisol levels,
which have been positively associated with increased exposure to psychosocial
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stressors.39-41 This could be problematic for African American (AA) men, who bear a
disproportionate burden of incidence and mortality of PCa, compared to European
American (EA) men,42-46 and have been shown to have increased cortisol production
directly linked to cumulative stressful life events.40 In addition, there is evidence of
dysregulated GR signaling due to hypersensitive GRs in AA men.41,47 Recent studies
demonstrated that glucocorticoid treatment, which is included in PCa therapy
regimens,12,48,49 induced dynamic changes in CpG methylation as well as transcription of
neighboring genes within an AA cohort, and disease enrichment analysis of Dex-induced
genes revealed associations with aging-related diseases including cancers.41
It is well established that AA men are diagnosed with a more aggressive PCa
phenotype attributable to the interplay between a number of factors including
socioeconomic status, access to healthcare, diet and lifestyle, and biological
contributors.42,43,45,46,50-62 However, it has yet to be explored whether the endogenously
elevated glucocorticoid signaling in AA men that has been linked to cumulative stressful
life events plays a role in the aggressive PCa phenotype and mortality disparities
observed in this population. In this overall context, we examined the contribution of GR
signaling to upregulation of LEDGF/p75 and CLU in a racially diverse panel of PCa cell
lines, and explored the transcript expression of GR in racially diverse PCa tissues.

Materials and Methods
Cell Lines, Antibodies, and Reagents
All cell lines were purchased from the American Type Culture Collection
(ATCC) and grown in a humidified incubator with 5% CO2 at 37o. In accordance with
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recent guidelines by the NIH on authentication of key biological resources, cells were
authenticated utilizing Short Tandem Repeat (STR) profiling against the ATCC STR
database (ATCC, Cat: ATCC 135-XV). Cells were routinely tested for mycoplasma
contamination using MycoAlert PLUS Mycoplasma Detection Kit (Lonza, Cat:LT07).
PC3 (Cat:CRL-1435), DU145 (Cat:HTB-81), and 22Rv1 (Cat:CRL-2505) cell lines were
cultured in RPMI 1640 medium (Corning, Cat:10-040-CV) supplemented with 10% fetal
bovine serum (Corning, Cat:35010CV), penicillin-streptomycin (Corning, Cat:30001Cl),
and gentamicin (Gibco, Cat:15710064) as recommended by the supplier. MDA-PCa-2b
(Cat:CRL-2422) cell line was cultured in F-12K medium (ATCC®, Cat:30-2004)
supplemented with 20% fetal bovine serum (Corning, Cat:35010CV), cholera toxin
(Sigma-Aldrich, Cat:C8052), epidermal growth factor (Sigma-Aldrich, Cat:E4127), ophosphoethanolamine (Sigma-Aldrich, Cat:P0503), hydrocortisone (Sigma-Aldrich,
Cat:H0888), selenious acid (ACROS Organics, Cat:AC19887), bovine insulin (SigmaAldrich, Cat:I6634), and penicillin-streptomycin as recommended by the supplier. 0.2%
Normocin (Invivogen, Cat:ANT-NR-1) was added to the medium for PC3, DU145,
22Rv1, and MDA-PCa-2b cell lines to prevent contamination by mycoplasma, bacteria,
or fungi.
Cortisol (Sigma-Aldrich, Cat:H0888) and Dex (Sigma-Aldrich, Cat:D4902)
reconstituted in ethanol were used at 10 nM concentrations as GR agonists while
mifepristone (Mif) (Sigma-Aldrich, Cat:M8046) reconstituted in ethanol was used at
100nM concentration as a GR antagonist. DHT (Cat: D073) reconstituted in ethanol was
used at 1 nM and 10 nM concentrations as AR agonists while enzalutamide (Enz) (HY70002 Medchem Express) reconstituted in ethanol was used at 1 M as an AR antagonist.
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In all experiments incorporating cortisol, Dex, Mif, DHT, or Enz, charcoal-stripped fetal
bovine serum (Atlanta Biologicals, Cat:S11650) was used in order to selectively remove
hormones while avoiding non-specific loss of other serum components. For experiments
exceeding 24 hours, media was replaced every 24 hours to ensure that cells would have
consistent exposure to glucocorticoids.
The following commercially-acquired antibodies were used: rabbit polyclonal
anti-LEDGF/p75 (1:1000, Bethyl Laboratories Inc., Cat:A300-848A), mouse monoclonal
anti-GR (1:1000, BD Biosciences, Cat:611226), mouse monoclonal anti-clusterin-chain
(1:1000, Millipore, Cat:05-354), rabbit monoclonal anti-AR (1:1000, Cell Signaling, Cat:
5153S), rabbit monoclonal anti-β-actin (1:5000, Cell Signaling, Cat:5125), rabbit
polyclonal anti--tubulin (1:1000, Cell Signaling, Cat:2148S).

Immunoblotting Procedures
Immunoblotting was performed as described previously.79 Briefly, equal amounts
of protein from whole cell lysates (5 g for MDA-PCa-2b and 22Rv1; 20 g for PC3 and
DU145) were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE, NuPAGE 4–12%, Thermo Fisher Scientific, Cat:NP0321BOX) and
transferred into polyvinyl difluoride membranes (Millipore, Cat:IPFL00010). Membranes
were blocked in 5% dry milk prepared in TBS-T buffer (20 mM Tris- HCl, pH 7.6, 140
mM NaCl, 0.1% Tween 20). Membranes were then probed individually with primary
antibodies and corresponding secondary antibodies and washed several times with TBS-T
between each antibody application. Enhanced chemiluminescence (ECL) was used to
detect immunoreactive protein bands. For this, the ECL Western Blotting Substrate
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(Thermo Fisher Scientific Pierce, Cat:32106) was added to the antibody-protein surface
of each membrane, followed by incubation for 4 minutes. Membranes were then
transferred to autoradiography cassettes and exposed to autoradiography films for
different lengths of time to ensure accurate detection of immunoreactive protein bands.
Protein bands from at least 3 independent experiments for each treatment were quantified
using ImageJ Software. The ratios of CLU or LEDGF/p75 protein bands to the loading
control bands (tubulin or -actin) were normalized to one in control, untreated samples.
This was then used to calculate the fold-upregulation of CLU and LEDGF/p75 in the
treated samples. Depending on the cell line, we used either tubulin or -actin as loading
controls since we observed in initial experiments that glucocorticoids induced -actin in a
cell line-dependent manner.

Quantitative Real-Time PCR
Quantitative Real-Time PCR (qPCR) was performed as described previously.79
Briefly, Total RNA was extracted from cells using the RNeasy Plus Mini Kit (Qiagen,
Cat:74134). The iScript cDNA synthesis kit (BioRad, Cat:1708891) was used to reverse
transcribe RNA (0.5 μg) into cDNA. qPCR was performed using the MyiQ real-time
PCR detection system with primers using iQ SYBR Green Supermix (BioRad,
Cat:1708882) following manufacturers’ recommendations. Primer sequences for
LEDGF/p75, Clusterin, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
designed using Primer 3 software. The forward sequence for LEDGF (5′ to 3′) was
TGCTTTTCCAGACATGGTTGT and reverse sequence (5’ to 3′) was
CCCACAAACAGTGAAAAGACAG. The forward sequence for Clusterin (5’ to 3’) was
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CTCTACTCTCCGAAGGGAATTGTC and reverse sequence (5′ to 3′) was
CGGGCTGCCTGTGCAT. GAPDH mRNA was used for normalization and the forward
sequence (5′ to 3′) was GAGTCAACGGATTTGGTCGT and reverse sequence (5′ to 3′)
was TTGATTTTGGAGGGATCTCG. Primers were commercially synthesized by
Integrated DNA Technologies (IDT). Data was normalized to values of corresponding
untreated controls and analyzed in at least three independent experiments, each in
triplicates.

RNA Interference-Mediated Knockdown of GR in PCa Cells
To achieve transient knockdown of GR in our cellular models, commerciallyavailable specific short inhibitory Trisilencer-27 RNAs (Origene, Cat:SR301960)
corresponding to Locus ID: 2908 were used as described previously.33 Cells were
transfected in a pooled knockdown with 10 nM of each siRNA Trisilencer-27/DicerSubstrate duplex using oligofectamine (Invitrogen, Cat:12252011) following
manufacturer's instruction. A universal scrambled negative control siRNA duplex
(Origene, Cat:SR30004) was used as a negative control. Quantification of protein bands
in immunoblots was performed as indicated above.

Cell Migration
In order to evaluate the migratory response of PC3 and DU145 cells following
exposure to Dex, a scratch wound healing assay was performed. Cells were seeded to
confluency and grown for 24 hours in RPMI 1640 medium supplemented with 10%
charcoal-stripped FBS, with or without 10 nM dexamethasone. Wound areas were
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generated using a 200 µl pipette tip by scratching the cell surface confluent monolayer.
Migration of cells into the wound areas was visually tracked using an Olympus IX70
microscope equipped with SPOT RT3 Imaging System and phase contrast images were
captured at 0 and 24 hours. The wound recovery rate of migrating cells obtained in 6
independent experiments was measured using ImageJ Software.

Identification of GR Binding Sites
The consensus for the GR binding sites was created using WebLogo.80 The 30
sequences (15 base long GR binding sites) used as input are shown in Supplementary
Table S1. The same sequences were used to create a letter probability matrix
(Supplementary Table S2). The CLU and LEDGF/p75 promoters were scanned for
putative GR binding sites with this matrix, using FIMO within the MEME Suite 4.12.0.
For the identification of GR binding half sites a PERL script was used that was developed
in-house. Promoters were searched for 6 base long half sites with appropriate
degeneracies, the search was then expanded on either the 5' or the 3' end depending upon
the half-site that was detected.

Bioinformatics Analysis of Oncomine Cancer Gene Microarray Database
For analysis of mRNA expression of GR, encoded by the NR3C1 gene, in PCa
and normal prostate tissues, we selected 10 datasets from the Oncomine database
(Compendia Biosciences; Ann Arbor, MI; www.oncomine.org). These datasets, derived
from gene microarray analyses of PCa and normal prostate tissues, provide fold-change
data for gene expression with P values calculated by Oncomine using Student’s t-tests.
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Two out of the 10 datasets, Wallace and Taylor, included ethnicity/race data. The
Wallace dataset included 41 prostate tissue specimens from AA men and 46 from EA
men while the Taylor dataset included 24 AA PCa and 115 PCa EA specimens in
addition to 2 Asian and 5 Hispanic PCa tissue samples. 29 normal adjacent tissue samples
were racially pooled. This allowed us to compare the NR3C1 transcript expression
between tissues from AA and EA patients.

Statistical Analysis
SPSS Statistics Software V22.0 and GraphPad Prism 6 were used for statistical
analyses. Differences between treatment groups were analyzed using unpaired Student’s
t-test. P values below 0.05 were considered statistically significant. All differences
highlighted by asterisks were statistically significant as encoded in figure legends (*P <
0.05; ** P < 0.01; ***P < 0.001; ****P<0.0001).

Results
Activated AR Signaling Upregulates LEDGF/p75 and CLU in 22Rv1 Cells
The GR bypass hypothesis posits that GR takes over the regulation of AR-target
genes after treatment of advanced PCa with primary and secondary ADT.1 Although
CLU is known to be androgen regulated,18,20,22 there are no studies determining that
LEDGF/p75 expression is also stimulated by androgen exposure in PCa cells. To explore
this, we examined the protein expression levels of LEDGF/p75 and CLU in androgen
responsive 22Rv1 PCa cells following exposure to dihydrotestosterone (DHT) and the
secondary ADT drug enzalutamide (Enz). We treated cells with either 1 nM DHT, 10 nM
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DHT, or 1 M Enz for 24 hours, and collected total lysates of both treated and untreated
cells to perform immunoblotting analyses using antibodies specific for either LEDGF/p75
or CLU. We observed increased protein levels of both LEDGF/p75 and CLU in cells
treated with either 1 nM or 10 nM DHT, which was attenuated by exposure to 1 M Enz
(Figure 9). These results were consistent with the previously reported upregulation of
CLU in PCa cells by androgens, and also provided evidence for androgen induction of
LEDGF/p75 in PCa cells.
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Figure 9. Androgen-induced upregulation of LEDGF/p75 and CLU in 22Rv1 cells. Cells
were treated for 24 hours with 1 nM DHT, 10 nM DHT, or 1 M Enz. Untreated (U) cells
were used as controls. Whole cell lysates were prepared for Western blotting and probed
with anti-LEDGF/p75 and anti-sCLU antibodies. Results from two independent
experiments were quantified with ImageJ. Results reveal a trend of increased LEDGF/p75
and CLU expression in 22Rv1 cells treated with DHT. Enz attenuated LEDGF/p75 and
CLU expression. All blots represented within panels are derived from the same gel.
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Activated GR Signaling Uupregulates LEDGF/p75 and CLU Protein Expression in
PCa Cells, Most Robustly in Cell Lines Carrying Substantial African Ancestry
We measured the protein expression of LEDGF/p75 in a racially diverse panel of
cell lines expressing GR—i.e. MDA-PCa-2b (AA), 22Rv1 (AA/EA), PC3 (EA), and
DU145 (EA)—following exposure to glucocorticoids, and compared the modulated
expression to matched untreated control cells. In a recent study we validated the
previously reported African ancestry of the MDA-PCa-2b cell line, as well as the
reported European ancestry of the PC3 and DU145 cell lines, using a panel of 29
validated Ancestry Informative Markers.63 Through this ancestry analysis, we also
established that the 22Rv1 cell line, whose racial ancestry origin had not been previously
reported, had mixed genetic ancestry, with substantial African ancestry.64 We treated
these cell lines with either 10 nM cortisol or 10 nM dexamethasone (Dex) for up to 48
hours, and collected total lysates of treated and untreated cells for immunoblotting
analyses using an antibody specific for LEDGF/p75. We observed increased LEDGF/p75
protein expression in MDA-PCa-2b, 22Rv1, and PC3 cells treated with glucocorticoids
(Figure 10A-C), with the most robust upregulation observed in MDA-PCa-2b cells and
the highest statistical significance achieved in both the MDA-PCa-2b and 22Rv1 cell
lines. Both cortisol and Dex treatments led to decreased protein expression of
LEDGF/p75 in DU145 cells (Figure 10D). Interestingly, while 22Rv1 cells upregulated
LEDGF/p75 protein expression after 24 hours of glucocorticoid exposure, MDA-PCa-2b,
PC3, and DU145 cells required 48 hours of exposure to glucocorticoids to observe
significant changes in LEDGF/p75 expression. Since we consistently found that Dex
treatment induced a more robust modulation of LEDGF/p75 protein expression than
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cortisol in our PCa cellular models, all subsequent experiments were conducted with Dex,
a highly specific and potent GR agonist.65
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Figure 10. Glucocorticoids robustly increase LEDGF/p75 protein expression in PCa cells
with substantial African ancestry. Cells were treated every 24 hours with 10 nM or 100 nM
Dex or cortisol for up to 48 hours. Untreated (U) cells were used as controls. Whole cell
lysates were prepared for Western blotting and probed with anti-LEDGF/p75 antibodies.
Results from at least 3 independent experiments were quantified with ImageJ as described
in the Methods section. Results reveal increased LEDGF/p75 expression in MDA-PCa-2b
(A), 22Rv1 (B), and PC3 (C) cells treated with glucocorticoids. Unpaired t-test statistical
analysis revealed that LEDGF/p75 induction in cell lines with substantial African ancestry
(MDA-PCa-2b and 22Rv1) achieved the highest statistical significance. *p<0.05,
**p<0.01, ***p<0.005. All blots presented within the panels are derived from the same
gel.
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Next, we treated our racially diverse panel of cell lines with 10 nM Dex and
collected total lysates of treated and untreated cells to determine the upregulation of CLU
using an antibody specific for the -chain of CLU capable of detecting both psCLU and
sCLU. While conducting immunoblotting and exposing the membranes to
autoradiography film, we consistently observed a very intense upregulation of sCLU
protein in the MDA-PCa-2b and 22Rv1 cell lines, which carry substantial African
ancestry, compared to the EA PC3 and DU145 cell lines, which expressed relatively low
levels. This prevented us from accurately quantifying sCLU protein expression levels in
these cell lines and comparing them with those in PC3 and DU145. Because of this, in
subsequent experiments we loaded only 5 g of total protein in individual lanes of gels
for MDA-PCa-2b and 22Rv1 cells, compared to 20 g of total protein for PC3 and
DU145 cells. After adjusting the protein loading amounts to better match band intensity
across cell lines, we continued to observe a statistically significant increase in sCLU
protein expression in MDA-PCa-2b and 22Rv1 cells, compared to PC3 cells, despite
loading 75% less protein in the individual lanes (Figure 11A-C). In agreement with the
results with LEDGF/p75, the most robust sCLU upregulation was consistently observed
in the cell lines with substantial African ancestry—MDA-PCa-2b and 22Rv1 (Figure
11A-B), whereas treatment of DU145 cells with Dex did not alter the expression of CLU
(Figure 11D). Interestingly, both ps-CLU and sCLU were modestly upregulated by Dex
in PC3 cells (Figure 11C).
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Figure 11. Glucocorticoids robustly increase CLU protein expression in PCa cells with
substantial African ancestry. Cells were treated every 24 hours with 10 nM Dex for up to
48 hours. Untreated (U) cells were used as controls. Whole cell lysates were prepared for
Western blotting and probed with anti-CLU antibodies recognizing both pre-secreted and
secreted CLU (psCLU and sCLU). Results from at least 3 independent experiments were
quantified with ImageJ as described in the Methods section. Results reveal increased sCLU
expression in MDA-PCa-2b (A), 22Rv1 (B), and PC3 (C) cells treated with Dex. Unpaired
t-test statistical analysis revealed that CLU increase in cell lines with substantial African
ancestry (MDA-PCa-2b and 22Rv1) achieved the highest fold change compared to
untreated controls. *p<0.05, **p<0.01. All blots represented within panels are derived
from the same gel.
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LEDGF/p75 and CLU Transcript Levels Increase in Response to Activated GR
Signaling
We next determined if the observed elevation in protein expression of
LEDGF/p75 and CLU in cells exposed to 10 nM Dex also occurred at the transcript level.
For this we conducted qPCR analysis of LEDGF/p75 and CLU transcripts in MDA-PCa2b, 22Rv1, PC3, and DU145 cells exposed to Dex, using the same experimental
conditions described above. Consistent with our immunoblotting results, we observed a
significant increase in LEDGF/p75 and CLU transcript expression in MDA-PCa-2b,
22Rv1, and PC3 cells exposed to 10 nM Dex, compared to untreated cells, with
significant decrease in transcript expression in DU145 cells (Figure 12A-D).
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Figure 12. Glucocorticoids increase transcript levels of LEDGF/p75 and CLU in PCa cells.
Cells were treated every 24 hours with 10 nM Dex for up to 48 hours. Untreated (U) cells
were used as controls. Total RNA was extracted from MDA-PCa-2b, 22Rv1, PC3, and
DU145 cells. Results from at least 3 independent qPCR experiments revealed LEDGF/p75
and CLU transcript levels increased in MDA-PCa-2b (A), 22Rv1 (B), and PC3 (C) cells
exposed to 10 nM Dex. LEDGF/p75 and CLU transcript levels decreased in DU145 (D)
cells. Unpaired t-test statistical analysis was used to assess statistical significance (*p<0.05,
***p<0.001, ****p<0.0001).
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Pharmacological Inhibition of GR Reduces Glucocorticoid-Induced Protein
Expression of LEDGF/p75 and CLU in 22Rv1 Cells
Given that our initial experiments demonstrated glucocorticoid-induced
upregulation of LEDGF/p75 and CLU expression in MDA-PCa-2b, 22Rv1, and PC3
cells, it was necessary to further explore if GR contributes to this upregulation. For these
experiments, we inhibited GR function using the GR antagonist mifepristone (Mif). To
overcome the inducing effects of 10 nM Dex, we used a concentration of 100 nM Mif.
We treated 22Rv1 and PC3 cells with 10 nM Dex in the presence or absence of 100 nM
Mif in order to compare the effect of GR inhibition on the Dex-induced upregulation of
LEDGF/p75 and CLU. Immunoblotting analysis showed that 100 nM Mif attenuated the
upregulation of LEDGF/p75 and sCLU protein expression induced by 10 nM Dex in
22Rv1 cells (Figure 13A). However, this significant attenuation was not observed for
LEDGF/p75 or psCLU in PC3 cells (Figure 13B).
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Figure 13. Pharmacological inhibition of GR attenuates glucocorticoid-induced protein
expression of LEDGF/p75 and CLU in 22Rv1 cells. 22Rv1 and PC3 cells were co-treated
with 10 nM Dex and 100nM Mif for up to 48 hours. Untreated cells were used as controls.
Whole cell lysates were prepared for Western blotting analysis and probed with anti-GR,
anti-LEDGF/p75, and anti-sCLU antibodies. Unpaired t-test statistical analysis revealed
that Mif attenuated LEDGF/p75 and CLU expression in 22Rv1 cells (A). However, this
attenuation was not observed in PC3 cells. (B). (*p<0.05)
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GR Knockdown Reduces Protein Expression of LEDGF/p75 and CLU in PCa Cells
Recognizing that Mif is not entirely specific for GR since it has been shown by
others to be a GR agonist under certain conditions,66 we sought to specifically target GR
to determine if it plays a more direct role in the glucocorticoid induction of LEDGF/p75
and CLU. For these experiments we transiently knocked down GR using a pool of short
inhibitory RNAs (siRNAs) specific for GR in 22Rv1 and PC3 cells. These siRNAs target
the Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1) gene, which encodes
GR. Transient knockdown of GR with siRNAs (si-GR) in 22Rv1 and PC3 cells led to
significant depletion of LEDGF/p75 and CLU proteins compared to cells transfected with
scrambled duplex siRNA (si-SD) control (Figure 14A-B). Taken together, these results
suggested a direct contribution of GR to glucocorticoid-induced upregulation of
LEDGF/p75 and CLU in PCa cells.

114

A

si

-S

D

si

-G

22Rv1

R

1.5

si-SD control
si-GR

GR

FoldChange

LEDGF/p75
ps-CLU
sCLU
b-actin

1.0

**

***

0.0
48 hours

GR

R
D
- S i-G
s
si

B

**

0.5

LEDGF/p75

ps-CLU

1.5

FoldChange

ps-CLU
Tubulin

sCLU

PC3

GR
LEDGF/p75

***

si-SD control
si-GR

1.0

*
*

0.5

***

48 hours

0.0
GR

LEDGF/p75

ps-CLU

Figure 14. GR knockdown attenuates LEDGF/p75 and CLU protein expression in PCa
cells. Transient knockdown of GR was generated in 22Rv1 and PC3 cells (si-GR). Gel
electrophoresis using whole cell lysates of si-GR compared to the scrambled control (siSD control) were probed with anti-GR, anti-LEDGF/p75, and anti-sCLU antibodies.
Unpaired t-test statistical analysis revealed that knockdown of GR in 22Rv1 (A) and PC3
(B) cells attenuated the protein expression of LEDGF/p75 and CLU (*p<0.05, **p<0.01,
***p<0.005). All blots represented within panels are derived from the same gel.
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Glucocorticoid Signaling Modulates PCa Cell Migration
Both glucocorticoid treatment and LEDGF/p75 depletion have been shown
previously to decrease the migration of DU145 cells and breast cancer cells.35,37,67 This
led us to examine the ability of glucocorticoids to alter the migration rate of PC3 and
DU145 cells using scratch wound healing assays. We chose these two cell lines because
of their ability to form a confluent monolayer, in contrast with the MDA-PC-2b and
22RV1 cell lines, which typically grow in clusters. After creating a wound area and
treating cells with 10 nM Dex, we captured images of the cell cultures at 0 hours and 24
hours in order to track cell migration in treated versus untreated cells. We observed a
marked and significant increase in the rate of migration of Dex-treated PC3 cells,
compared to untreated cells, such that closure of the wound area occurred at 24 hours
(Figure 15A). However, the opposite effect was observed in DU145 cells, as the rate of
migration was significantly reduced in Dex-treated cells compared to untreated cells
(Figure 15B).
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Figure 15. Glucocorticoid signaling modulates PCa cell migration. Phase contrast images
of scratch wound healing assays used to measure the migration of PC3 and DU145 cells
were captured with an Olympus IX70 microscope. PC3 and DU145 cells treated with 10
nM Dex or untreated controls at 0 and 24 hours after the scratches were made at the same
point. Unpaired t-test statistical analysis revealed that treatment with 10 nM Dex increases
PC3 cell migration (A) but decreases DU145 cell migration (B). Scale bar=200 µm;
(**p<0.01, ****p<0.0001).
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GR Binding Sites Identified in Promoter Regions of LEDGF/p75 and CLU
To further explore the possibility that GR regulates the glucocorticoid induction
of LEDGF/p75 and CLU in PCa cells, likely by binding to the promoter regions of these
genes, we conducted a PubMed literature survey of GR promoter binding sites as well as
an in-silico promoter analysis. These resulted in a comprehensive list of GR binding sites
(Table 4) that have already been experimentally validated. The 49 previously identified
GR binding sites ranged from 7 to 35 bases in length (Table 4), with 30 of these being 15
bases long. We used the sequences of these 30 GR binding sites to build a consensus GR
binding element using WebLogo (Figure 16).
From the consensus sequence, it could be derived that the GR binding site in most
cases consists of two half-sites, which are six base inverted repeats, separated by 3
degenerate bases (Figure 16). We observed that the last three bases (4-6) of the first (5')
half-site and the first three bases (10-12) of the second (3') half-site are highly conserved
(Figure 16). To determine if a similar 15 base long putative GR binding site is present in
the promoters of LEDGF/p75 and CLU, we scanned these promoters with a letter
probability matrix (Table 5) derived from their sequences, using FIMO,68 a webtool,
within the MEME Suite 4.12.0. Putative GR binding sites were detected in both CLU
(AGCACAGGAAGTATT; P<0.0001) and LEDGF/p75 (GAAACCCTACGTCCC;
P<0.0008) promoters, in the reverse strands between 132-146 bases and 611-625 bases,
respectively (Figure 16; Table 6).
We also observed from the list of experimentally validated GR-binding sites
(Table 4), that a half-site is sufficient to bind GRs and the two half-sites may sometimes
be separated by four instead of three bases.69-71 Taking these into consideration we
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scanned the two promoters for the half-sites with the help of an in-house PERL script and
identified at least two half-sites in each of the two promoters (Table 6). This in-silico
analysis suggested that there are multiple putative GR binding sites within the
LEDGF/p75 and CLU promoters to which GR might bind and regulate the expression of
these genes.

119

Table 4. GR Binding Sites
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Table 5. Letter Probability Matrix
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Figure 16. GR binding sites in LEDGF/p75 and CLU promoter regions. The GR binding
consensus derived from experimentally validated sites is aligned with the putative GR
binding sites within the promoters of CLU and LEDGF/p75. Light gray shading
indicates the conserved half-sites.
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Table 6. Putative GR Binding Sites Within LEDGF/p75 and CLU Promoter Regions
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Analysis of Cancer Gene Microarray Datasets Reveals Race/Ethnicity-Related
Differential Expression of GR Transcript in PCa Tissues
Next, we sought to examine GR expression (NR3C1 gene) in human PCa tissues.
Transcript expression of NR3C1 in PCa tissues, compared to normal prostate tissue, was
analyzed using 10 PCa gene microarray datasets from the Oncomine database. NR3C1
was consistently downregulated in prostate tumors compared to normal prostate tissues in
9 of the 10 datasets (Figure 17A). The magnitude of the fold-decrease was modest, with
only 5 datasets showing >1.5-fold downregulation and the remaining 4 datasets with >1fold decrease. However, the P values were <0.001 in 7 datasets, indicating that GR
downregulation was highly significant in PCa tissues compared to normal tissues.
Most of the Oncomine datasets examined above have no racial/ethnic identifiers.
However, two datasets, Wallace and Taylor, had gene expression data for PCa tissues
from different racial/ethnic groups. When grouping the NR3C1 transcript expression data
by race/ethnicity, box-plots of the log2 median-centered intensity in the Wallace dataset
showed that the median value was slightly higher in prostate tissues from AA men
(3.065) as compared to EA men (2.993) (Figure 17B). The Taylor dataset displayed a
much higher log2 median-centered intensity NR3C1 transcript in AA (0.589) PCa tissues
compared to EA (0.272) and Asian (-0.134) PCa tissues. Interestingly, the NR3C1 median
expression levels in AA PCa tissues was slightly lower than that in PCa tissues from
Hispanic patients (0.64) in the Taylor dataset. Unfortunately, we did not have access to
racial identifiers for the Hispanic patients. It is noteworthy that the Wallace dataset
grouped the normal adjacent prostate tissues with prostate tumors for the race/ethnicitybased analysis, while the Taylor dataset grouped the normal adjacent and PCa tissues

125

separately, which may account for the differences in NR3C1 expression between AA and
EA PCa tissues observed in these two datasets.
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Figure 17. Expression of GR/NR3C1 transcript between clinical prostate cancer
tissues specimens from AAs and EAs in Oncomine. Transcript expression levels of
GR/NR3C1 in prostate tumors versus normal prostate tissues was derived from cancer gene
microarray datasets in Oncomine database. Individual dataset names appear in the legend
boxes at the right (A). Box-plots from the Wallace and Taylor datasets were used from
Oncomine gene microarray database (B). Fold-changes and corresponding P-values for the
differences in gene expression between PCa and normal prostate tissues were obtained
from Oncomine. The number of samples in each dataset is different, therefore higher fold
change does not always correspond to statistical significance. *P<0.05, **P<0.01,
***P<0.001.
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Discussion
Understanding the mechanism(s) by which GR signaling activates AR-target
genes in the absence of androgens has high relevance to the development of effective
treatments for advanced PCa.1,4-9 The downstream effects of this GR bypass include
promotion of tumor aggressiveness as well as resistance to standard PCa therapies such
as ADT and potentially taxane chemotherapy.4,6,15 While key stress oncoproteins
associated with increased PCa cell survival in the presence of environmental stressors
such as chemotherapeutic drugs have been identified and at times targeted in pre-clinical
and clinical studies (e.g., CLU, LEDGF/p75, HSP27, PRDXs), there remains a need to
understand the potential contribution of glucocorticoid signaling to the activation and
upregulation of these proteins. With this goal in mind, this study was designed to
examine the contribution of glucocorticoid signaling to the expression of CLU and
LEDGF/p75, two stress oncoproteins previously established as key contributors to
therapy resistance in various cancer types.17,19-21,24-27 The roles of CLU and LEDGF/p75
in the acquisition and maintenance of resistance to standard PCa therapies have been
established; however, this study is the first to implicate GR signaling in their upregulation
in PCa cells. Multiple recent studies have linked GR signaling to PCa disease
progression,1,4,6-9,15,72 but to our knowledge none of these studies have compared GR
signaling events in racially diverse pre-clinical cellular models, or explored GR
expression in racially diverse PCa tissues.
In this study, we observed that exposure to glucocorticoids led to upregulation of
CLU and LEDGF/p75 transcript and protein levels in three out of four PCa cell lines, and
that GR blockade attenuated this effect. Moreover, the most robust upregulation was
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observed in the two PCa cell lines with substantial African ancestry, MDa-PCa-2b, and
22Rv1. Although many investigators have assumed for years that 22Rv1 is a EA PCa cell
line, we recently conducted a DNA ancestry analysis on this cell line using a panel of 29
validated Ancestry Informative Markers, and reported that it is a mixed ancestry PCa cell
line comprised of 0.41 West African, 0.42 European, and 0.17 Ameri-Indian ancestral
proportions.63,64
Our finding that CLU expression is highly responsive to glucocorticoids in MDAPCa-2b and 22Rv1 cells is underscored by our decision to decrease substantially the
amount of total protein from these two cell lines that were loaded in individual lanes of
gels for immunoblotting. For instance, when we loaded 20 g of protein per lane from
MDA-PCa-2b and 22Rv1 cells, CLU protein expression was so dramatically elevated that
we were unable to differentiate individual lanes within the blots, even after decreasing the
exposure time. Conversely, CLU protein expression was relatively lower in PC3 and
DU145 cells when individual lanes in gels were loaded with 20 g of protein from these
cells. The observed high endogenous expression of CLU in the MDA-PCa-2b and 22Rv1
cell lines could suggest that downstream effects of GR signaling such as the upregulation
of therapy-resistance associated genes may be exaggerated in AA PCa patients. This
would be consistent with the emerging notion that GR signaling is enhanced in the AA
population.41,47
Interestingly, we observed downregulation of LEDGF/p75 and CLU in DU145
cells exposed to glucocorticoids, which was consistently opposite from the results
observed in MDA-PCa-2b, 22Rv1, and PC3 cells. This was expected as other
investigators have reported that GR activation decreases the aggressive properties of the
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DU145 cell line while its blockade reverses this effect .65,73-75 The impact of activated GR
signaling on PCa cells includes the promotion of tumor aggressiveness properties leading
to worse overall patient survival.4 Tumor aggressiveness develops when normal cellular
functions are altered and established hallmarks of cancer such as increased cell migration
are induced.76 We observed that Dex treatment significantly increased the migration rate
in PC3 cells but not that of DU145 cells, suggesting a cell-type dependent effect. These
results are consistent with our observation that GR induced downregulation of
LEDGF/p75 in DU145 cells, and previous reports that LEDGF/p75 depletion or
treatment with Dex decreased the migration rate of DU145 PCa cells.35,67 Several
potential mechanisms have been proposed to explain these DU145-specific effects,
including relatively higher GR expression compared to other PCa cell lines, which could
lead to immediate downregulation of GR and shutdown of GR signaling upon exposure
to glucocorticoids.65,75
The ability of glucocorticoids to upregulate LEDGF/p75 and CLU in PCa cell
lines appears to be mediated by GR. This was confirmed by our observation that
pharmacological or genetic blockade of GR led to significant downregulation of
LEDGF/p75 and CLU expression. Although it remains to be established that GR binds
directly to and activates promoter regions of these two genes, our in-silico analysis
confirmed the presence of multiple putative GR binding sites within both LEDGF/p75
and CLU promoter regions, which would allow for direct regulation by activated GR.
Recent studies have demonstrated that GR expression is reduced in primary PCa
tissues but increases in metastatic lesions, particularly in patients who have received
DTX therapy.6,15 Since these analyses were conducted mostly in PCa tissues from EA
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patients, we asked whether primary PCa tissues from AA men also express reduced levels
of GR. Our analysis of 10 cancer gene microarray datasets from the Oncomine database
revealed that GR (encoded by NR3C1 gene) transcript was consistently downregulated in
prostate tumors compared to normal prostate tissues, in agreement with the previous
reports.6,15 However, when we focused our analysis on GR expression based on racial
classification, we observed differences between AA and EA PCa patients. Both the
Wallace and Taylor datasets, which contain gene expression data from AA PCa tissues,
revealed higher median values of GR in AA prostate tissues compared to EA prostate
tissues. Unfortunately, there was no information in the datasets regarding the
chemotherapy treatment status of the tissue donors. Nevertheless, these findings are
consistent with the premise that AA men with PCa may have enhanced intratumoral GR
signaling.
We speculate that the recently documented hyperactive GR signaling occurring in
AA men41,47 could exacerbate the upregulation of LEDGF/p75 and CLU in PCa cells. It
is possible that chronically elevated cortisol levels, increased GR levels, and hyperactive
GR signaling sustained in AA men over time could prime them to develop aggressive
PCa tumors. In addition, this enhanced GR signaling could induce a robust expression of
oncoproteins associated with therapy-resistance, including LEDGF/p75 and CLU, leading
to poor response to conventional treatments in AA PCa patients.
The results of this study also complement the growing body of literature
suggesting that glucocorticoid co-administration with PCa therapies including ADT may
potentially lead to worse overall patient survival.1,4,6,9-11 By upregulating oncoproteins
associated with resistance to ADT and taxane chemotherapy, activated GR signaling may
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promote the proliferation and migration of highly aggressive PCa tumor cells with
enhanced therapy resistance capabilities. For instance, our findings that GR activation
increased CLU could offer insights into why recent clinical trials targeting CLU with an
antisense oligonucleotide-based drug, Custersin, in combination with taxane
chemotherapy in advanced stage PCa patients were ineffective.77,78 It is plausible that
CLU and other pro-survival proteins were activated by GR as patients in both study arms
received glucocorticoid co-therapy to mitigate side effects.
The implications of our findings are far-reaching as GR is emerging as a key
driver of PCa tumor aggressiveness, especially in the absence of AR signaling. Since our
results demonstrate that LEDGF/p75 and CLU are upregulated in the absence of
androgen via GR, future combinatorial therapies co-targeting AR, GR, and stress
oncoproteins could potentially confer greater overall survival to patients with advanced
PCa. In addition, given that AA men display an enhanced physiological response to
glucocorticoids as well as disproportionate PCa incidence and mortality, further studies
are needed to better elucidate the relationship between GR signaling and PCa tumor
aggressiveness specifically in this racial/ethnic group.
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CHAPTER FOUR
PHYSICIAN CONSULTATIONS, PROSTATE CANCER KNOWLEDGE, AND
PSA SCREENING OF AFRICAN AMERICAN MEN IN THE ERA OF SHARED
DECISION-MAKING

Abstract
African American (AA)/Black men are more likely to develop aggressive prostate
cancer (PCa), yet less likely to be screened despite guidelines espousing shared decisionmaking regarding PCa screening and prostate-specific antigen (PSA) testing. Given the
documented racial disparities in PCa incidence and mortality, engaging interactions with
physicians are especially important for AA/Black men. Thus, this study evaluated
occurrence of physician-patient conversations among AA/Black men, and whether such
conversations were associated with PCa knowledge. We also quantified the serum PSA
values of participants who had, and had not, discussed testing with their physicians. Selfidentified AA/Black men living in California and New York, ages 21-85, donated blood
and completed a comprehensive socio-demographic and health survey (n=414). Less than
half (45.2%) of participants had discussed PCa screening with their physicians.
Multivariate analyses were used to assess whether physician-patient conversations
predicted PCa knowledge after adjusting for key socio-demographic/economic and health
care variables. Increased PCa knowledge was correlated with younger age, higher
income and education, and having discussed the pros and cons of PCa testing with a
physician. Serum PSA values were measured by ELISA. Higher-than-normal PSA values
were found in 38.5% of men who had discussed PCa screening with a physician and
29.1% who had not discussed PCa screening. Our results suggest that physician-
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AA/Black patient conversations regarding PCa risk need improvement. Encouraging
more effective communication between physicians and AA/Black men concerning PCa
screening and PSA testing has the potential to reduce PCa health disparities.

Introduction
Prostate cancer (PCa) is the most commonly diagnosed male cancer in the U.S,
and African American (AA) men are 2.5 times more likely to die from this malignancy
than European American (EA) men.1,2 Early detection through timely screening and
optimal treatment options improve overall survival, yet AA and other Black men of
African ancestry are not as likely to receive these health advantages as EA men.1-6 With
the implementation of the Affordable Care Act, the gap in access to high-quality health
care, timely diagnosis, and optimal treatment has narrowed between AAs and EAs.7
However, even under equal access to health care, disparities in PCa treatment and
screening options still persist.7-9
PCa diagnosis involves prostate-specific antigen (PSA) screening.1,10-12
Circulating serum PSA levels are considered abnormal when detected above 4 ng/ml.10
While the U.S. Food and Drug Administration approved the use of PSA testing in
conjunction with digital rectal examination (DRE) to screen asymptomatic men for PCa
in 1994, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation
against PSA-based screening in 2012.10 This recommendation was based on the
assumption that, for most men, screening has no net benefit or the harms may outweigh
the benefits10 The recommendation influenced the current American Academy of Family
Physicians’ overarching stance to “not routinely screen for PCa using a PSA test or
DRE”. However, decreased screening differentially affects “patient populations under
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consideration” which includes AA men.10 This is because the USPSTF report
acknowledged that no firm conclusions about the benefits-to-harm ratio of PSA screening
can be drawn in AA men due to their limited representation in the clinical trials that
supported the recommendation against PSA screening.10 A more recent study that used
Surveillance, Epidemiology, and End Results (SEER) data to investigate survival
disparities between AA (n=23,782) and EA (n=188,937) men comparing pre-PSA testing
era to current-PSA testing era provided a compelling case for continued aggressive PSA
testing for AA men.11 Additionally, frequent and early PSA testing has been suggested
for AA men in order to reduce racial disparities in PCa mortality.11,12
Previous USPSTF guidelines recognized that before offering PSA
screening, shared decision-making should occur through an engaged physician-patient
conversation that enables informed choice based on patient preferences.10 The American
Academy of Family Physicians currently advises that physicians offering PSA screening
be “prepared to engage in shared decision-making that enables an informed choice by
patients”. The American Cancer Society (ACS) also encourages informed decisionmaking and recommends PCa screening at age 50 for men at average-risk, 45 for men at
high-risk, and 40 for men at higher-risk. ACS includes AA men in the high-risk category
and recommends repeated annual PCa screening for men with PSA levels >2.5 ng/ml.
While informed decision-making is the current recommendation for PCa screening,
recent studies highlight that AA men may not be making informed decisions about PCa
screening.13 This is largely due to patients having limited knowledge of PCa screening
and providers either not offering sufficient up-to-date information or not asking patients
about their preferences.13 Therefore, there is a need for more engaging interactions
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regarding PCa screening between physicians and patients, especially for AA and other
Black men of African ancestry, who are more likely to develop aggressive end-stage PCa
at an earlier age. Knowledge of PCa and screening among AA/Black men may therefore
play a critical role in reducing PCa health disparities.
AA/Black men in the U.S. comprise a heterogeneous population that includes
both native- and foreign-born individuals, and nativity can affect individual health
outcomes.14,15 Our survey data from a cohort of self-reported AA/Black men in two U.S.
geographical regions focused on assessing men’s knowledge of PCa in light of clinical
provider interactions. We explored factors potentially influencing PCa knowledge among
AA/Black men, including whether their physicians had discussed PCa screening with
them. Additionally, PSA values of participants were assessed to demonstrate the real-life
value of PSA screening in this high-risk population.

Materials and Methods
Participant Cohort
Cross-sectional data were collected via Project C.H.A.N.G.E (Changing Health
for Adult Men with New and Great Experiences), in Riverside, CA in 2013 and
Brooklyn, NY in 2014. Recruited through community outreach, a convenience sample of
adult men either donated blood or completed a 141-item health survey, or both, after
written informed consent. While all study participants self-identified as Black, some
participants further self-identified as AA and others as Caribbean Black or African. For
discussion purposes we grouped them under the general term of AA/Black. This study
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was conducted under approval of Loma Linda University Institutional Review Board
(OSR#5110343).

Serum Collection
Blood was drawn by licensed staff and collected in red top vials. Collected blood
rested at room temperature for 30 minutes to allow clotting. Serum was separated from
blood cells by centrifugation, transferred to polypropylene tubes, and transported in dry
ice for permanent storage at -80C.

PSA ELISA
Human PSA ELISA Kits were purchased from Abnova (Taoyuan City, 320
Taiwan, catalog #KA0208). The 96-well ELISA plates were pre-coated with goat antiPSA antibody for serum PSA detection. Following completion of the health fairs, sera
from study participants who donated blood samples were added to the wells and
circulating PSA was allowed to bind to the immobilized antibody. Wells were washed to
remove unbound PSA. Monoclonal anti-PSA-horseradish peroxidase conjugate was then
added to each well and allowed to bind PSA. Wells were washed and TMB (3,3’,5,5’
tetramethylbenzidine) reagent (provided in kit) was added to each well followed by
incubation. Color development was interrupted with Stop Solution (provided in kit), and
absorbance was measured by spectrophotometer at 450 nm, with PSA concentration
directly proportional to color intensity. PSA values were calculated from a standard curve
generated using PSA standards provided with the kit. PSA measurements were performed
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in duplicates for all serum samples. To ensure IRB compliance, individual PSA values
were de-identified and not disclosed to study participants.

Statistical Analysis
Socio-demographic, socio-economic, and health care variables were evaluated
using validated items from LaVeist and Deibert national surveys. Age was assessed as a
continuous variable ranging from 21 to 85 years. Income was originally a categorical
variable with 23 groups. We created a continuous distribution of income by constructing
a new variable in which we estimated the midpoint of each group. We estimated the
lowest group (0 to $5000) at $1000 and the top income group (more than $350,000) at
$750,000. The resulting approximate income distribution was skewed. To minimize the
skew, we took the log of the distribution and used this log transformation in our analyses.
Education was coded as a categorical variable with three levels: high school graduate or
below; some college or associate’s degree; and college graduate and above. To measure
participant trust of health care providers and organizations, an 18-item adapted version of
the LaVeist Medical Mistrust Index was used. Items were summed and normalized to the
original four-point Likert scale, with higher scores indicating higher mistrust. Knowledge
of PCa was assessed using 11 items modified from Deibert et al.’s scale. For each
true/false question, a correct response was coded with a value of “1”, while an incorrect
response or unanswered item was coded with a “0”. All items were then summed. Thus,
a higher score represents higher PCa knowledge. Respondents who did not complete any
knowledge questions or other relevant, nearby survey sections were excluded from the
analysis (n=3). Categorical variables with yes/no responses included whether participants
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had health insurance, were told by a physician that they had PCa, or ever discussed the
pros and cons of PCa screening with a physician. Descriptive analysis was performed to
explore distributions and describe the sample (Table 7). Multivariate analysis was
conducted with the following variables: age, education (college graduate and above as the
reference group), log income, health insurance, medical mistrust, ethnicity, whether a
physician had told the respondent that he had PCa, and whether a physician had discussed
with the respondent the pros and cons of testing. Hierarchical models were developed,
but only the final model is presented (Table 8). Prior to analysis, data were screened for
linearity, normality, and homoscedasticity. Except for income, no transformations were
made. Based on Mahalanobis testing, no outliers were excluded. Statistical analysis was
performed using IBM SPSS 23.
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Table 7. Descriptive Statisticsa
Variables
Dependent Variable
Prostate Cancer Knowledge
Demographic Variables
Foreign-Born Blacks
Age
Socioeconomic Status
High school graduate or below
Some college or associate’s degree
College graduate and above
Logged Income
Has Health Insurance
Medical Beliefs & Experience
Medical Mistrust Scale
Diagnosed with Prostate Cancer
Doctor Discussed Screening Pros/Cons
Tested for Prostate Cancer
Had PSA Test
Had Digital Rectal Exam
Note: a. n= 414
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Range

Mean or
Percentage

Standard
Deviation

0 – 11

7.9

2.2

0 – 100
21 – 85

60.6
48.9

14.5

0 – 100
0 – 100
0 – 100
6.91 – 13.53
0 – 100

29.0
38.6
32.4
10.6
68.1

1–4
0 – 100
0 – 100
0 – 100
0 – 100
0 – 100

2.5
3.9
45.2
39.1
21.0
34.3

1.2

0.38

Table 8. Multivariate Modeling of Predictors of PCa Knowledge

Variable
Ethnicity
Age
Education
High school graduate or
below
Some college or Associate’s
degree
Income
Health insurance
Medical mistrust
Told has prostate cancer
Discussed pros/cons of testing
Constant
R-square

Coefficient
.069
-.024

Standard
Error
.2128084
.0081818

95% CI
-.3492875 .487776
-.0403466 -.0081642

p Value
0.745
0.003

Referent
U.S.-Born Blacks
Not applicable

-.983

.2826495

-1.538938 -.4271609

0.001

College graduate and above

-.730

.2417114

-1.20496 -.254209

0.003

College graduate and above

.373
-.007
.306
-.535
.482
5.315
0.16

.0906024
.2307852
.2631934
.5159006
.2312566
1.306724

0.000
0.976
0.245
0.301
0.038
0.000

Not applicable
No health insurance
Not applicable
Yes, told has prostate cancer
Discussed pros/cons

.1945511
-.4609131
-.2114296
-1.549288
.0272432
2.745492
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.5509279
.4468605
.8238191
.4799626
.9368714
7.885378

Results
Univariate Analyses
Only participants who provided written consent, donated blood, and completed
the survey were included in our analyses (n=414). Men with a previous prostate cancer
diagnosis (16/414, 3.9%) were included in analyses. We evaluated ethnicity in two
groups: U.S.-born (163/414) AA men and foreign-born (251/414) Black men living in the
U.S. Within the foreign-born group, 85.8% (215/251) of participants were from the
Caribbean West Indies. Descriptive characteristics of study participants are shown in
Table 7. Within the cohort, 45.2% (187/414) of participants reported having spoken with
their physicians about the pros and cons of PCa screening.

Multivariate Analyses
Regression analysis (Table 8) assessed the relative contribution of correlates on PCa
knowledge. Results indicate that PCa knowledge was inversely associated with age and
positively associated with income. Compared to those with a high school degree or less,
men who had a college degree or above, or had some college education or Associate’s
degree, reported higher PCa knowledge scores. Importantly, after adjusting for the
variables identified in Table 7, men who discussed the pros and cons of testing with their
physicians reported higher PCa knowledge. Non-significant variables included not having
health insurance, level of medical mistrust, having been told he has PCa, ethnicity, and
the length of stay in the U.S. of the foreign-born participants (data not shown).
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PSA Values in the Context of PCa Screening Conversations with Physicians
ELISA was used to quantify serum PSA levels in men participating in the study.
Average PSA levels increased with age, with levels in men in their 30s averaging 0.8
ng/ml and men in their 80s averaging 16.4 ng/ml (Figure 18). Results revealed that 12.1%
(50/414) of participants had higher-than-normal PSA levels when using the conventional
cutoff >4 ng/ml. Of these, 38.0% (19/50) had never discussed the pros and cons of PCa
screening with a physician (Figure 19). Additionally, 9.4% (39/414) of all the men in the
study cohort had detectable PSA levels between 2.5-3.9 ng/ml, and 48.7% (19/39) of
these had not discussed the pros and cons of PCa screening with a physician (Figure 19).
Further, 11.8% (49/414) of total participants had detectable PSA levels between 1.5-2.49
ng/ml, and of these, 57.1% (28/49) had never discussed the pros and cons of PCa
screening with a physician (Figure 19). Thus, 33% (138/414) of all participants had PSA
values above 1.5 ng/ml, and of these, 47.8% (66/138) had not discussed PCa screening
with their physicians. The remaining 66.7% (276/414) had PSA levels <1.5 ng/ml (Figure
19).
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Figure 18. PSA values of AA/Black study participants differentiated by reported normal
cutoffs. Serum PSA levels in sera of the study participants were determined by ELISA. As
expected, average PSA levels increased with age, with PSA of men in their 30s averaging
0.8 ng/ml and PSA of men in their 80s averaging 16.4 ng/ml. We identified participants
who had higher-than-normal PSA in the context of differing numerical values for what is
considered higher-than-normal PSA levels for AA men. While the conventional cutoff for
higher-than-normal PSA levels is 4 ng/ml, the American Cancer Society currently advises
repeat screening for men with PSA levels greater than 2.5 ng/ml, and one study suggests
1.5 ng/ml as a predictor for PCa in AA men.16 Our results revealed that 33.3% of study
participants had higher-than-normal PSA levels. Of these, 12.1% of participants (50/414)
had PSA levels >4 ng/ml, 9.4% (39/414) had detectable PSA levels between 2.5-3.9 ng/ml,
and 11.8% (49/414) had detectable PSA levels between 1.5-2.49 ng/ml.

153

Figure 19. PSA values of study participants who had discussed PCa screening with their
physicians vs. those who had not. Diagram illustrating the percentage of participants with
PSA values considered as high-risk separated into groups by those who had discussed the
pros and cons of PCa screening versus those who had not. Of the total study participants,
54.8% (227/414) had never discussed the pros and cons of PSA testing with their
physicians. Of these, 29.1% (66/227) had higher-than-normal PSA values as determined
using the three cutoff values defined in Figure 18. Conversely, 45.2% (187/414) of study
participants had discussed the pros and cons of PSA testing with their physicians. Of these,
38.5% (72/187) had higher-than normal PSA values as determined using the three cutoff
values defined in Figure 18.
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Discussion
In light of the disproportionately high disparities in PCa incidence and mortality
affecting AA/Black men, recent recommendations espouse earlier screening for this
group.11,12 USPSTF guidelines are also currently undergoing a process of revision,
although a full recommendation statement has not been finalized. The current draft under
consideration includes a level C recommendation that clinicians inform men ages 55-69
about the potential benefits and harms of PSA-based screening for PCa, with a
recommendation against PSA-based screening in men 70 years and older. A widespread
endorsement of clinician conversations regarding PCa screening would be beneficial as
studies have shown that a better understanding of PCa by AA/Black men is critical for
reducing these disparities since knowledge of this disease strongly influences informed
decision-making.8
Several factors are associated with PCa knowledge among AA/Black men,
including physician consultation. An important component of physician conversations
with patients regarding PCa screening involves discussing the potential benefits and
harms of testing.8 Ideally, these conversations should culminate in increased PCa patient
knowledge to help steer choices regarding screening and treatment.13 However,
AA/Black men are less likely to receive sufficient information from their physicians
about PSA testing to make an informed decision. 13
Recognizing these concerns, this study evaluated the occurrence of physicianpatient conversations within an AA/Black men cohort and assessed whether this
translated into an increase in PCa knowledge and PSA testing. Our study represents a
novel step in that it focuses specifically on AA/Black men. Additionally, it assesses
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whether having discussed PCa screening with a physician is associated with higher PCa
knowledge. Our study approach was also unique in that the responses were aligned with
newly quantified PSA levels. We identified participants who had higher-than-normal
PSA, recognizing that PCa experts assign differing cutoff values for what is considered
higher-than-normal PSA levels for AA/Black men. For instance, while the conventional
cutoff for higher-than-normal PSA is 4 ng/ml, ACS now recognizes PSA >2.5 ng/ml as
reason for repeat annual screening, and one study suggests >1.5 ng/ml for AA men.10,16
Therefore, we determined the percentage of men under these PSA cutoff values
separately. This study is also the first to report high-risk AA/Black men with higher-thannormal PSA values who had yet to discuss the pros and cons of PCa testing with their
physicians. While elevated PSA does not inevitably predict PCa, these findings were
distinctive as it has been reported that 1 in 4 AA/Black men will be diagnosed with PCa,
yet 1 in 3 of our AA/Black participants had elevated PSA levels, which could be
indicative of underlying PCa. We cannot rule out, however, that elevated PSA levels in
some participants may be unrelated to PCa.
Multivariate analysis revealed that PCa knowledge increased as age decreased, as
income and education increased, and in men who had discussed the pros and cons of
testing with their physicians. This suggests that increased physician interaction with lesseducated and lower-income men is critical, given that these groups are less likely to
access health care or navigate their discussions with physicians as easily as their peers
with higher income and education. Our findings also suggest that AA/Black men in their
40s may not have the knowledge they need to consider their high risk for PCa while
making a decision about screening.
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As expected, PSA values in our AA/Black male cohort increased with age.
Approximately one-third of participants had PSA values that could be considered higherthan-normal; however, over half of the men had never discussed the pros and cons of
PSA testing with their physicians. This is problematic as this high-risk population should
be well-informed about PCa risk and screening options. Our results reveal that the
physician-patient conversations may not be occurring frequently enough in a population
with existing higher-than-normal PSA values, which includes AA/Black men under 40
years old. However, we recognize that there are no current recommendations for PCa
screening for men in their 20s and 30s.
A limitation of this study is that participants were not instructed to accurately
identify the type of physician or healthcare provided they interacted with (e.g. family
physician, urologist, nurse practitioner, etc), which may have impacted the emphasis
placed on a PCa screening conversation. Because of this limitation, we did not explore
measures of physician competency that may have impacted the efficacy of these
conversations. Another potential limitation is that the study was conducted within a
church-based (Seventh-Day Adventist) population and urban areas of California
(Riverside) and New York (Brooklyn), which are likely to attract men who are more
aware about their health and about cancer prevention.17 To counterbalance the potential
confounding factor of religion on survey responses as well as increase community
involvement, we also recruited non-church affiliated men through local Black-owned
barbershops for our Riverside event and from community organizations in Brooklyn.
Nevertheless, consistent with previous findings, faith-based organizations are promising
venues for health promotion in AA/Black communities.17 We also experienced during the

157

course of our study that these organizations provide an excellent venue and mechanism
for the recruitment of AA/Black men for community-based participatory research.
Encouragingly, the physician-patient conversations that are occurring regarding
PCa screening appear to be effective, as verified by subsequent PCa knowledge
assessment. There is room for improvement, however, as we found that for many men
who exhibited high PSA values and had discussed with their physicians the pros and cons
of PCa screening, these discussions did not translate to actual PSA testing in 24% of this
subgroup of men. This study further highlights the continued need for effective
communication between physician and patient regarding prostate health and PCa
screening and for better provider education about the special needs of AA men, which
may not have been adequately addressed under existing procedural recommendations.
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CHAPTER 5
SELECTED UNPUBLISHED DATA

Patient Sera Samples Used in ELISAs
Sera from patients with PCa were obtained from Loma Linda University (LLU)
Cancer Center Biospecimen Laboratory, Bioserve (Beltsville, MD), LLU Medical Center,
and the serum bank in the LLU Center for Health Disparities and Molecular Medicine.
Normal human sera were obtained from the serum bank in the Cancer Autoimmunity
Research Laboratory of The University of Texas at El Paso (UTEP) and used as controls.
These non-PCa sera were collected during annual health examinations in adults who had
no obvious evidence of malignancy or autoimmune disease. We collected additional nonPCa sera under approval of LLU Institutional Review Board (OSR#5110343) during
community Black Men’s Health Fairs held in Riverside, California, and Brooklyn, New
York organized under Project C.H.A.N.G.E. (Changing Health in Adults with New and
Great Experiences), a LLU community outreach initiative comprised of a
transdisciplinary team of scientists and health care professionals.

Enzyme-Linked Immunosorbent Assays (ELISAs)
Commercially-available ELISA kits were used to quantify circulating
LEDGF/p75 (MyBioSource, Cat:MBS706164) and sCLU (Boster, Cat:EK0914)
according to manufacturers’ instructions. 96-well plates provided within the kits were
pre-coated with capture antibody specific for either LEDGF/p75 or sCLU. Briefly,
human sera were added to the wells and circulating LEDGF/p75 or sCLU was allowed to
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bind to the immobilized antibody. Wells were washed to remove unbound LEDGF/p75 or
sCLU. Anti-LEDGF/p75 or anti-sCLU horseradish peroxidase conjugate was then added
to each well and allowed to bind to LEDGF/p75 or sCLU. Wells were washed and TMB
(3,3’,5,5’ tetramethylbenzidine) reagent (provided in kit) was added to each well
followed by incubation. Color development was interrupted with Stop Solution (provided
in kit), and absorbance was measured by spectrophotometer at 450 nm, with LEDGF/p75
or sCLU concentration directly proportional to color intensity. LEDGF/p75 and sCLU
values were calculated from a standard curve generated using standards provided with the
kits. LEDGF/p75 and sCLU measurements were performed in duplicates for all serum
samples.

LEDGF/p75 and CLU May Circulate at Higher Levels in Sera of AA Men
Compared to EA Men
We used ELISAs specific for either LEDGF/p75 or CLU to quantify circulating
levels of the proteins in the sera of AA and EA PCa patients. We also included normal
AA and EA patient controls. There was no statistically significant difference found in
levels of circulating LEDGF/p75 between AA and EA PCa patients, between normal and
PCa patients, or between AA and EA normal patients (Figure 20). However, there were 3
outlier patients whose circulating LEDGF/p75 levels greatly exceeded the levels of all
other patients. All 3 of these outlier patients were AA PCa patients. In terms of CLU,
there were statistically significant differences in circulating levels within sera of our
patient samples (Figure 21). Interestingly, there was no statistically significant difference
between circulating CLU levels between AA PCa patients and AA normal patients.
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Rather, every AA normal patient was found to have CLU circulating at a level which
matched levels expected to be found in PCa patients.

163

Figure 20. Elevated circulating LEDGF/p75 observed in AA PCa patients.
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Figure 21. Elevated circulating CLU observed in AA normal men matching levels
observed in AA and EA PCa patients. (*p<0.05, ***p<0.001).
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Dex transactivates the CLU promoter
Our observations led us to further investigate if Dex plays a direct role in
transactivating the promoters of CLU and LEDGF/p75. To determine this, a
luciferase transcription reporter assay was performed in a preliminary experiment
using PC3 cells. Cells were transfected with either pGL4.10-Vec, pGL4.10-CLU, or
pGL4.10-ledgf/p75. PC3 cells untreated with Dex but transfected with pGL4.10-CLU
or pGL4.10-ledgf/p75 displayed significant increase in promoter transactivation, as
measured by relative light units of luciferase activity, when compared to cells
transfected with pGL4.10-Vec (Figure 22). More importantly, PC3 cells treated with
10 nM Dex and transfected with pGL4.10-CLU displayed significant increase in
promoter transactivation, as measured by relative light units of luciferase activity,
when compared to cells transfected with pGL4.10-Vec. PC3 cells treated with 10 nM
Dex and transfected with pGL4.10-ledge/p75 displayed a slight increase in promoter
transactivation, as measured by relative light units of luciferase activity, when
compared to cells transfected with pGL4.10-Vec, however the increase was not
significant. Results from this experiment are preliminary and will be repeated in the
future in order to report statistical significance in terms of fold change.

166

*

Relative light units

15000

10000

****
***

****
****

5000

pG
pG
L4
L4
.
1
pG
.10
0
L4
-cl
.10
u
Ve
[
-cl
No c
u
De
[10
x]
nM
De
x]
pG
L4
pG .10L4
p
.10
led GL4
.10
gf
led /p75
-Ve
gf/
p7
c
[N
5
oD
ex
[10
]
nM
De
x]

0

Figure 22. 10 nM Dex robustly transactivates CLU promoter in luciferase-based
transcription reporter assay using PC3 cells. A slight increase in transactivation was
observed in LEDGF/p75 promoter. (*p<0.05, ***p<0.001, ****p<0.0001).
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CHAPTER 6
OVERALL DISCUSSION
PCa is the most commonly diagnosed cancer and the second leading cause of
cancer death among men in the U.S.1 For 80 years, it has been established that androgens
are needed to drive PCa development and progression, and for this reason ADT drugs
targeting androgen synthesis and AR have been a mainstay treatment for PCa patients.2
While ADT is successful in most patients who choose this option, ADT-resistance is
inevitable and PCa progresses to mCRPC.3 Taxane chemotherapy is available to mCRPC
patients in the form of DTX and CTX, but these treatments are not long-lasting or
curative.4-6 Once chemoresistance inevitably occurs, there are no further treatments
available and palliative care is the only remaining option to improve patient comfort.7
Because PCa cells escaping organ-confinement develop castration-resistance and
chemoresistance in response to PCa treatments, there is an urgent need to identify new
molecular targets that may confer greater benefit and increase longevity.8
Until recently, the mechanism behind the acquisition of ADT-resistance in PCa
cells and the ability to progress in the absence of androgens had not been fully elucidated.
Pivotal studies within the last five years have proposed that, in the absence of androgens
and functional AR, activated GR can bypass the classical AR pathway and bind AREs
within the promoter regions of AREs thereby transactivating canonical AR-target genes
associated with tumor aggressiveness.9-14 Complementing these reports were studies that
demonstrated increased GR expression within ADT-resistant and chemoresistant preclinical PCa cellular models and patient samples.10,15 The implications of these findings
were troublesome as PCa patients are routinely administered synthetic glucocorticoids as
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co-therapy alongside ADT and taxane chemotherapy for palliative purposes to reduce
adverse side effects.12,16-18 Unfortunately, patients co-administered glucocorticoids with
Enz or abiraterone had worse overall survival outcomes in two separate clinical trials.12,19
Under normal cellular conditions, GR signaling is activated when glucocorticoids bind to
GR, GR translocates the nucleus, and binds to GREs transactivating GR-target genes.20 In
the context of ADT-resistance, however, GR appears to activate both GR- and AR-target
genes.10
The prospect of GR driving advanced PCa progression is potentially amplified in
AA men who, alongside suffering a disproportionate rate of PCa incidence and mortality,
are also reported to have amplified GR signaling and excessive cortisol.1,21-23 There is
evidence that chronic stress throughout the lifetime of AAs leads to dysregulation of
endogenous cortisol production via the HPA axis, and this HPA dysregulation is well
documented to enhance risk for metabolic disorders and cancer.22-25 The HPA axis is
activated in response to stress, and there is a positive association between stress and
lower SES in AA men.22,26 Decreased SES is defined by lesser income, education, or
occupation and often results in increased exposure to environmental stressors leading to
stress-related dysregulation of physiological systems and increased risk for disease.22,27,28
While lower SES is associated with dysregulation of cortisol diurnal rhythm, AAs also
wake with lower cortisol levels and sustain higher cortisol levels in the evening
suggesting a dysregulation of normal cortisol diurnal rhythm that cannot be explained by
SES.22 The long-term consequences of this dysregulation are complicated and
problematic for the health of AAs,23,29,30 and the overall role of altered GR signaling in
the context of PCa health disparities has not been previously explored.
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The cause of PCa health disparities documented in AA men are complex and
include many contributing factors such as socioeconomic issues, biological and genetic
determinants, diet, lifestyle, and access to healthcare,31-38 The compounding effect of
these factors lead to AA men being diagnosed with exaggerated biological characteristics
of PCa including higher PSA levels, higher Gleason scores, and advanced tumor stage.3941

Men are more likely to be diagnosed with more advanced stages PCa when proper

screening protocols are not observed.42 Deciding when and whom to screen for PCa has
been a topic of hot debate since screening recommendations were drastically altered in
2012 in favor of significantly reduced PSA testing.43 While a caveat encouraging
conversations between physicians and AA men regarding shared-decision making was
provided within the USPSTF grade D recommendation against PSA testing, this study
explored whether these conversations were occurring as well as effective.
We recruited over five hundred men to participate in Black Men’s Health Fairs in
Riverside, CA and Brooklyn, NY and complete a comprehensive socio-demographic and
health survey as well as donate blood for research purposes.44 Disturbingly, we found that
less than half (45.2%) of participants had ever discussed the pros and cons of PCa
screening with their physicians. We then adjusted for key socio-demographic/economic
and health care variables and performed multivariate analyses to assess whether
physician-patient conversations predicted PCa knowledge.44 We found that increased PCa
knowledge was correlated with younger age, higher income and education, and having
discussed the pros and cons of testing with a physician.44 These results suggested that
although many physicians were not having important shared-decision making
conversations with their AA patients, physicians who did discuss PCa screening with
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their AA patients were communicating effectively.44 When we analyzed existing
circulating PSA values by ELISA in these same participants, we detected higher-thannormal levels in 38.5% of men who had discussed PCa screening with a physician and
29.1% of men who had not discussed PCa screening.44 Taken together, there is room for
improvement as a third of the AA study participants had elevated circulating PSA, a
biomarker used in PCa screening, yet many of these men had never discussed PCa
screening with their physicians.44 Our results highlight the need for improved screening
practices among AA men at high-risk of developing aggressive PCa.44
Given the reports of enhanced GR signaling in this racial/ethnic group in
conjunction with emerging studies documenting the important role of GR in PCa tumor
aggressiveness and therapy-resistance, this study also sought to explore the potential
relationship. Understanding how biological factors contribute to health disparities
requires mechanistic functional analysis of specific genes or pathways in pre-clinical
cellular models of this malignancy. To accomplish this task, it is essential to have
available a well-characterized and racially diverse patient-derived cohort of immortalized
cell lines representing different stages of PCa. Unfortunately, there is currently a lack of
racial diversity in the human PCa cell lines that are commercially available for research,
thereby limiting the scope of in vitro addressing mechanistic events involving potential
biological factors associated with PCa health disparities.45 Recognizing the importance
of well-characterized and authenticated cell lines to ensure validity of published reports,
the NIH recently established guidelines concerning the authentication of key biological
resources including cell lines.45 This authentication also applies to racial identity for
studies exploring biological determinants of health disparities. In this context, we verified
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the racial identity of several cell lines essential to our studies while also establishing for
the first time that popular cell line 22Rv1, assumed to be EA for nearly two decades,
carries mixed genetic ancestry with substantial AFR composition.45
To determine our findings, we used a validated set of 29 SNP genotypes referred
to as AIMs and frequently used for population structure analyses.45,46 All the 29 selected
SNPs exhibited large allele frequency differences between four continental populations—
AFR, EUR, AMI, and EAS—and these differences were confirmed using the NCBI
dbSNP databse.46 SNP genotyping conducted at the UCLU Genomics Core revealed that
PC3 and DU145 cell lines, originally reported to be EA, carried majority EUR ancestry.45
In addition, MDA-PCa-2b and RC-77T/E cell lines, reportedly derived from AA patients,
carried majority AFR ancestry.45 The 22Rv1 cell line, long considered to be EA, was
found to carry the following ancestral proportions: 0.41 AFR, 0.42 EUR, and 0.17 AMI.45
Our valuable finding has provided an additional resource to advance molecular research
in the context of PCa health disparities.45
Once we validated the racial identifiers of each cell line required for our
mechanistic studies, we continued our quest to explore the relationship between GR
signaling and PCa health disparities. More specifically, we examined the ability of
activated GR to upregulate two key stress oncoproteins associated with PCa therapyresistance—LEDGF/p75 and CLU—and observed race-dependent differential
expression. To complement studies suggesting that activated GR bypasses the AR
signaling pathway and activates AR-target genes10,12, we first determined and validated
that LEDGF/p75 and CLU are regulated by androgens. Using AR agonist DHT and AR
antagonist Enz, we treated 22Rv1 cells which are AR-positive and -sensitive and
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observed that both LEDGF/p75 and CLU are regulated by androgens. Our findings
support other studies that have confirmed androgen-regulation of CLU.47-49
We next treated a racially diverse panel of PCa cell lines with GR agonists
cortisol and Dex to determine the ability of activated GR to upregulate LEDGF/p75
protein expression. LEDGF/p75 was upregulated in three out of four PCa cell lines with
the most robust fold change in protein expression observed in MDA-PCa-2b and 22Rv1
cells with substantial AFR ancestry. This same GR-mediated upregulation was observed
with CLU, and MDA-PCa-2b and 22Rv1 cells continued to the trend measured in
LEDGF/p75 with heightened intensity of CLU upregulation compared to EA cells. After
determining that activated GR upregulates LEDGF/p75 and CLU protein expression in
PCa cells, and most robustly in cells with substantial AFR ancestry, we assessed
transcript levels under the same experimental conditions. We found that activated GR
increased LEDGF/p75 and CLU transcript levels in three out of the four cell lines.
To further explore if GR contributes to LEDGF/p75 and CLU upregulation, we
pharmacologically inhibited GR with Mif. Using 22Rv1 and PC3 cells, we observed an
attenuation of LEDGF/p75 and CLU in 22Rv1 cells, but this same attenuation was not
observed in PC3 cells. Recognizing that Mif is not entirely specific for GR and has been
shown by others to be a GR agonist under certain conditions,50 we sought to specifically
target GR using transient knockdown with siRNAs specific for NR3C1. This genetic
blockade of GR led to significant depletion of LEDGF/p75 and CLU in both 22Rv1 and
PC3 cells.
We also examined the ability of glucocorticoids to modulate the migration rate of
PCa cells and chose PC3 and DU145 cells because of their abilities to form a confluent
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monolayer. We performed scratch wound healing assays after treating cells with Dex and
observed significantly increased migration in PC3 cells, yet significantly decreased
migration in DU145 cells. Our consistent observations that GR decreased migration in
DU145 cells in conjunction with repeated downregulation of LEDGF/p75 and CLU in
these cells when treated with glucocorticoids is consistent with other reports
demonstrating that high levels of basal GR in DU145 cells could lead to immediate
downregulation and shutdown of GR signaling upon exposure to glucocorticoids.51,52
To further explore the possibility that GR regulates the glucocorticoid induction
of LEDGF/p75 and CLU in PCa cells, likely by binding to the promoter regions of these
genes, we performed in silico analysis suggesting that there are multiple putative GR
binding sites within the LEDGF/p75 and CLU promoters to which GR might bind and
regulate the expression of these genes.
Upon determining that activated GR is able to upregulate stress oncoproteins
associated with PCa therapy-resistance—LEDGF/p75 and CLU—in PCa cells
differentially dependent upon race, we conducted Oncomine analysis to identify
transcript GR expression in primary prostate tissues from AA and EA men. We observed
that, consistent with other reports, that GR transcript was consistently downregulated in
PCa tumors compared to normal prostate tissues. However, when we focused our analysis
on GR expression based on racial classification, we observed higher median values of GR
in AA prostate tissues compared to EA prostate tissues. Our findings were consistent with
the premise that AA men with PCa may have enhanced intratumoral GR signaling.
We were also able to measure circulating levels of LEDGF/p75 and CLU using
serum samples from AA and EA men. Using ELISA we determined that, while there was
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no statistically significant difference found in levels of circulating LEDGF/p75 between
AA and EA PCa patients, between normal and PCa patients, or between AA and EA
normal patients, there were 3 AA PCa outlier patients whose circulating LEDGF/p75
levels greatly exceeded the levels of all other patients. In terms of CLU, every AA
normal patient was found to have circulating CLU at levels which matched both AA and
EA PCa patients. Further studies including more patient samples are needed to further
support our preliminary findings. However, our results suggest that AA men have
elevated circulating LEDGF/p75 and CLU, which may be attributed to amplified GR
signaling, priming them to develop more aggressive PCa tumors as well as acquire
resistance to standard PCa therapies.
Taken together, the implications of our findings are far-reaching as GR is
emerging as a key driver of PCa tumor aggressiveness.9,12,53 Our results indicate that this
effect may be amplified in AA men, and could provide a rationale for increased tumor
aggressiveness and worse outcome observed in this racial/ethnic group. Our findings also
complement the growing body of literature suggesting that glucocorticoid coadministration with PCa therapies including ADT may potentially lead to worse overall
patient survival.9,10,12,53-55 By upregulating oncoproteins associate with resistance to ADT
and taxane chemotherapy, activated GR signaling may promote the proliferation and
migration of highly aggressive PCa tumor cells with enhanced therapy resistance
capabilities. Since our results demonstrate that LEDGF/p75 and CLU are upregulated in
the absence of androgen via GR, future combinatorial therapies co-targeting AR, GR, and
stress oncoproteins could potentially confer greater overall survival to patients with
advanced PCa. There remains a need to further elucidate genes driven by GR signaling
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that are specifically associated with ADT-resistance as well as chemoresistance. Given
that AA men display an enhanced physiological response to glucocorticoids as well as
disproportionate PCa incidence and mortality, further studies are needed to better
elucidate the relationship between GR signaling and PCa tumor aggressiveness
specifically in this racial/ethnic group.
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CHAPTER 7
METHODOLOGY
The contents of this chapter are for the purpose of instructing current and future
laboratory members on the methodology utilized in this project. This section will provide
key details and insights that are important to reproduce the studies presented in this
dissertation and to troubleshoot common problems that could be encountered in followup studies.

Cell Culture
Each cell line has a specific protocol for growing conditions. Please refer to
ATCC Culture Methods section for current instructions. For this study, PC3, DU145, and
22Rv1 use the following culture conditions. Upon arrival of fresh cells from ATCC or
when thawing previously frozen stocks, thaw cells in warm water bath (37o C) without
submerging to prevent contamination. Once thawed, immediately pipette full volume of
cell suspension into T25 flasks pre-warmed with 5mL media. Incubation conditions are
95% air, 5% carbon dioxide, and 37oC. Cells will proliferate and attach quickly. The
following day, remove media (in order to remove DMSO present in freezing media) and
replace with fresh media. Once cells are confluent, expand cells to a T75 flask. The
media required for these cell lines consists of RPMI-1640 with 10% FBS. We also
supplement the 500 mL media bottle with 100 L of gentamycin and 1000 L of
normocin to prevent bacterial and fungal contamination. The subculture ratio for
expansion is 1:2 with media renewal every 2 to 3 days. To freeze cells in liquid nitrogen,
use complete growth media supplemented with 5% DMSO.
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MDA-PCa-2b cells have unique growing conditions. Upon arrival of fresh cells
from ATCC or when thawing previously frozen stocks, thaw cells in warm water bath
(37o C) without submerging to prevent contamination. Once thawed, immediately pipette
full volume of cell suspension into T25 flasks pre-warmed with 5mL media. Incubation
conditions are 95% air, 5% carbon dioxide, and 37oC. Cells will proliferate very slowly
for the first 3 weeks. This cell line never reaches full confluency and the morphology
appears as grapelike clusters rather than a uniform monolayer. After one week, expand
cells from one T25 to two T25 flasks. A week later, expand cells from 2 T25 flasks to 4
T25 flasks. The following week expand 4 T25 flasks to 1 T75 flask. At that point cells
can be expanded from 1 T75 into 2 T75 flasks. The media required for this cell line
consists of F12-K with 20% FBS. We also supplement the media with cholera toxin
(Sigma Aldrich, Cat:C8052), epidermal growth factor (Sigma Aldrich, Cat:E9644),
phosphoethanolamine (Sigma Aldrich, Cat:P0503), hydrocortisone (Sigma Aldrich,
Cat:H0135), selenious acid (Sigma Aldrich, Cat:229857), and insulin (Sigma Aldrich,
Cat:I0516).
The media preparation for MDA-PCa-2b is tedious and specific and should be
meticulously adhered to as follows. Remove 100 mL of F12K media (500 mL bottle) and
aliquot into two 50 mL tubes inside the sterile hood. Add 100 mL FBS to the F12K media
(500 mL bottle) inside the sterile hood. Add penicillin-streptomycin (either 5 mL of
10,000 units or 10 mL of 5,000 units). Take two 50 mL tubes of removed F12K media to
lab bench outside of sterile hood. Aliquot 10 mL of media into new 15 mL “master mix”
tube. Dissolve 0.5 mg of cholera toxin (1 mg/mL) in 500 L of media (use extra media
aliquoted from 50 mL tubes) (store in 4o C for future use). Add 12.5 L of dissolved
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cholera toxin into 15 mL “master mix” tube. Dissolve 0.1 mg epidermal growth factor in
250 L of media (use extra media aliquoted from 50 mL tubes) (store in 4o C for future
use). Add 12.5 l of dissolved epidermal growth factor into 15 mL “master mix” tube.
Add 250 uL of insulin (0.005 mg/mL) into 15 mL “master mix” tube. Dissolve 0.01 g of
selenious acid (45 mM) in 10 mL of media (use extra media aliquoted from 50 mL
tubes). Add 2.9 L into 15 mL “master mix” tube. Dissolve 1 mg of hydrocortisone (100
pg/mL) in 10 mL of media (use extra media aliquoted from 50 mL tubes) (store in 4o C
for future use). Add 0.5 L into 15 mL “master mix” tube. Dissolve 0.01 g of
phosphoethanolamine in 10 mL of media (use extra media aliquoted from 50 mL tubes).
Add 352 L into 15 mL “master mix” tube. Take 15 mL “master mix” tube back into
sterile hood and prepare to filter the contents of the “master” tube into the 500 mL bottle
of F12K. You will need a sterile disposable syringe that can hold 10 mL of liquid as well
as a disposable sterile syringe filter capable of screwing onto the disposable syringe.
Inside the sterile hood, remove the lid of the 500 mL F12K bottle and remove the
syringe from its packaging. Then remove the seal of the disposable sterile syringe filter.
Remove the sterile syringe filter and carefully balance on the exposed opening of the 500
mL F12K bottle. Carefully pour the contents of the “master mix” tube into the empty
plastic container that housed the sterile syringe filter. Draw up the contents of the “master
mix” tube that are now within the plastic container into the syringe. Dispense the entire
syringe contents through the filter into the F12K media bottle. To ensure that all bacteria
have been filtered out, aliquot 5 mL newly made complete media into empty T25 flask
and allow to grow at least 48 hours to rule out contaminated media. Make sure media is
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not contaminated prior to adding thawed cells. The subculture ratio for expansion is 1:2
with media renewal every 2 to 3 days. These cells cannot be frozen and rethawed.

Treatment of PCa Cells with AR- and GR-Binding Drugs
In our experiments, PCa cells were treated with different AR- and GR-binding
drugs at different concentrations for up to 48 hours. To ensure reproducibility and
efficiency, drugs should be handled following the instructions given by the manufacturer.
For example, to prepare 10nM Dex, dissolve the drug in solid form in the vehicle agent
ethanol. It is important to know what solvent to use to dissolve each drug considering
their solubility properties. The solubility of Dex in ethanol is 25mg/ml. The molecular
weight of Dex is 392.46. To prepare 10 nM stock, adhere to the following steps. It is
important to dilute each drug in serial dilutions to maintain proportion of drug to media
and equal distribution of particulate. Dissolve 0.4 g of Dex in 10 mL of ethanol (or 0.2 g
of Dex in 5 mL of ethanol) for final 100 mM stock concentration. Divide in aliquots of 20
mL and freeze the aliquots in -80oC not in use to ensure stability. From the 100 mM Dex
stock, dissolve 10 mL of 100 mM stock solution into 10 mL of charcoal-stripped media
for final 100 mM solution. From the 100 mM Dex solution, dissolve 10 mL into 10 mL
of charcoal-stripped media for final 100 nM solution. From the 100 nM solution, dissolve
1000 mL into 10 mL of charcoal-stripped media for final 10 nM solution. Charcoalstripped FBS is required when supplementing media in order to remove trace endogenous
hormone levels.
For experiments using cortisol or Dex exceeding 24 hours, media was replaced
every 24 hours to ensure that cells would have consistent exposure to glucocorticoids.
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The following drugs were obtained from these companies: Dex (Sigma-Aldrich,
Cat:D4902), cortisol (Sigma-Aldrich, Cat:H0888), Mif (Sigma-Aldrich, Cat:M8046),
DHT (Sigma-Aldrich, Cat: D073), Enz (HY-70002 Medchem Express), and charcoalstripped FBS (Atlanta Biologicals, Cat:S11650).

Immunoblotting Procedures
The following commercially-acquired antibodies were used for our studies: rabbit
polyclonal anti-LEDGF/p75 (1:1000, Bethyl Laboratories Inc., Cat:A300-848A), mouse
monoclonal anti-GR (1:1000, BD Biosciences, Cat:611226), mouse monoclonal anticlusterin-chain (1:1000, Millipore, Cat:05-354), rabbit monoclonal anti-AR (1:1000,
Cell Signaling, Cat: 5153S), rabbit monoclonal anti-β-actin (1:5000, Cell Signaling,
Cat:5125), rabbit polyclonal anti--tubulin (1:1000, Cell Signaling, Cat:2148S).
Whole cell lysates were prepared as follows. To collect cells, we detached them
from the surface of tissue culture flasks or plates using 1 mL of trypsin. Cell suspensions
were collected in 5 mL plastic tissue culture tubes and stored on ice. We then spun the
cells for 4 minutes in a clinical centrifuge at 4,000 RPM, discarded the supernatant
carefully, and washed the pellet with PBS by additional centrifugations. This step was
repeated 2 times to eliminate any residual trypsin and media. This is important because
albumin is highly abundant in medium and may interfere with electrophoresis and
immunoblotting if not adequately removed. We dissolved the pellet in Laemmli sample
buffer containing a protease inhibitor cocktail (LSB:CPI, volume depends on size of
pellet but typically we started with 100μl of this reagent for cells collected from two 6-

186

well plates seeded at 120,000 cells per well). Cells were sonicated on ice to disrupt
cellular structures. The lysates were stored at -80o C to preserve protein integrity.
Immunoblotting was performed following this procedure. Equal amounts of
protein from whole cell lysates were loaded into individual wells of 4-12%
polyacrylamide gradient gels (SDS-PAGE, NuPAGE, Thermo Fisher Scientific,
Cat:NP0321BOX). Protein concentration was determined utilizing the DC protein assay
kit from BioRad following the manufacturer’s instructions. To observe and compare
changes in protein expression between cell lines, only 5 μg-10 μg should be loaded onto
wells to avoid saturating the chemiluminescence signal in immunoblots. For other
applications, 15 μg to 20 μg is ideal but the sensitivity of the antibody should also be
considered. Proteins were separated by SDS- PAGE and transferred onto polyvinyl
difluoride membranes (PVDF) (Millipore, Cat:IPFL00010) in a NuPAGE electrophoresis
system by Thermo Fisher Scientific.
To prepare the samples after calculating the desired protein concentration, we
diluted the appropriate protein volume in 5 μl NuPAGE LDS sample buffer (4X) and 2 μl
of NuPAGE reducing agent (10X). Final volume, typically 20 μl, was achieved utilizing
deonized water. The buffers utilized were purchased from the manufacturer. The protein
separation was done in MOPS SDS running buffer and 500 L of antioxidant for 90
minutes at 175 volts. Other members of the lab perform protein separation for 60
minutes. However, for the purpose of further separating the proteins of interest in this
study, the migration time was extended to 90 minutes. The protein transfer was done in
transfer buffer diluted to a concentration of 1X (the buffer comes in a 20X concentration)
with 10% methanol and 70 L of antioxidant for 90 minutes at 25 volts.
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To visualize and confirm complete protein transfer, membranes were rocked
slowly at room temperature for 20 minutes in ponceau S stain. Membranes were then cut
at appropriate molecular weight to allow individual antibody probing. Membranes were
blocked in 5% dry milk prepared in TBS-T buffer (20 mM Tris- HCl, pH 7.6, 140 mM
NaCl, 0.1% Tween 20) for 1 hour. Blocking was done rocking slowly at room
temperature. Membranes were then probed individually with primary and allowed to rock
overnight in the cold room at 4oC. The next morning, membranes were washed 3 times
for 10 minutes with TBS-T and corresponding secondary antibodies were added to
membranes which rocked at room temperature for 2 hours. The dilution ratio varies
between antibodies and should be done following manufacturer’s instructions and inhouse optimization. For example, when utilizing a rabbit anti-LEDGF/p75 antibody by
the company Bethyl (1:1000, Bethyl Laboratories Inc., Cat:A300-848A), we incubated
with primary antibody at a 1:1000 dilution overnight rocking in the cold room. We then
washed with TBS-T 3 times, changing TBS-T every 10 minutes. Then, we applied the
appropriate secondary antibody for 2 hours in a wet chamber. After incubation, we
repeated the washing cycles. Enhanced chemiluminescence (ECL) was used to detect
immunoreactive protein bands. For this, the ECL Western Blotting Substrate (Thermo
Fisher Scientific Pierce, Cat:32106) was added to the antibody-protein surface of each
PVDF membrane, followed by incubation for 4 minutes. Membranes were then
transferred to autoradiography cassettes and exposed to autoradiography films for
different lengths of time to ensure accurate detection of immunoreactive protein bands.
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RNA Interference-Mediated Knockdown of GR in PCa Cells
To achieve transient knockdown of GR in our cellular models, commerciallyavailable specific short inhibitory Trisilencer-27 RNAs (Origene, Cat:SR301960)
corresponding to Locus ID: 2908 were used. Cells were transfected in a pooled
knockdown with 10 nM of each siRNA Trisilencer-27/Dicer-Substrate duplex using
oligofectamine (Invitrogen, Cat:12252011) following manufacturer's instruction. A
universal scrambled negative control siRNA duplex (Origene, Cat:SR30004) was used as
a negative control. To seed the cells in 6 well plates on day 1, we used antibiotic-free
media, which ensure that antibiotics do not interfere with the uptake of the siRNA oligos.
We also prepared the oligofectamine-siRNA complexes in serum-free media prior to
adding to cells plated in 6 well plates on day 2 since serum interferes with the formation
of these complexes. Cells were harvested on day 4 (48 hours following transfection).

Quantitative real-time PCR
When working with RNA, clean workspace with ethanol and RNase Eliminator.
Total RNA was extracted from cells using the RNeasy Plus Mini Kit (Qiagen,
Cat:74134). Briefly, cells reconstituted in RNAprotect Cell Reagent are thawed at room
temperature and then centrifuged for 5 minutes at 7000 RPM. Remove the supernatant
completely by pipetting and loosen the pellet by flicking the microcentrifuge tube. Add
600 L Buffer RLT Plus and dissolve the pellet completely by vortexing. Homogenize
the lysate with 25G needle and 1 mL syringe 5 times. Transfer the homogenized lysate to
a gDNA Eliminator spin column placed in a supplied 2 mL collection tube and centrifuge
for 30 seconds at 10,000 RPM. Discard the column and save the flow through. Add 1
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volume of 70% ethanol to the flow-through and mix well by pipetting. Transfer up to 700
L of the sample to an RNeasy spin column placed in a supplied 2 mL collection tube
and centrifuge for 15 seconds at 10,000 RPM. Discard the flow-through. Add 700 L
Buffer RW1 to the RNeasy spin column and centrifuge for 15 seconds at 10,000 RPM.
Discard the flow through. Add 500 L Buffer RPE to the RNeasy spin column and
centrifuge for 2 minutes at 10,000 RPM. Place the RNeasy spin column in a new supplied
1.5 mL collection tube. Add 30-50 L RNase-free water directly to the spin column
membrane and centrifuge for 1 minute at 10,000 RPM to elute the RNA.
The iScript cDNA synthesis kit (BioRad, Cat:1708891) was used to reverse
transcribe RNA (0.5 μg) into cDNA in duplicates. Briefly, prepare enough assay master
mix for all reactions by adding all required components in the following order (per
reaction): 1. 4 L iScript Reaction Mix, 2. 0.5 g RNA template, 3. 1 L iScript Reverse
Transcriptase, 4. Nuclease-free water (variable, add total volume 20 L – other reagents
listed 1-3.) Mix the assay master mix thoroughly and dispense equal aliquots into wells of
96-well qPCR plate. Seal 96-well plate with adhesive film (BioRad, Cat: MSB1001).
Program BioRad thermal cycling protocol on the real-time PCR instrument.
qPCR was performed using the MyiQ real-time PCR detection system with
primers using iQ SYBR Green Supermix (BioRad, Cat:1708882) following
manufacturers’ recommendations. Primer sequences for LEDGF/p75, Clusterin, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were designed using Primer 3
software. The forward sequence for LEDGF (5′ to 3′) was
TGCTTTTCCAGACATGGTTGT and reverse sequence (5’ to 3′) was
CCCACAAACAGTGAAAAGACAG. The forward sequence for Clusterin (5’ to 3’) was
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CTCTACTCTCCGAAGGGAATTGTC and reverse sequence (5′ to 3′) was
CGGGCTGCCTGTGCAT. GAPDH mRNA was used for normalization and the forward
sequence (5′ to 3′) was GAGTCAACGGATTTGGTCGT and reverse sequence (5′ to 3′)
was TTGATTTTGGAGGGATCTCG. Primers were commercially synthesized by
Integrated DNA Technologies (IDT). When preparing primer mix, add 8 L reverse
primer, 8 L forward primer, 64 L nuclease-free water. Thaw iQ SYBR Green
Supermix, cDNA, and primers in ice and vortex. For each reaction, prepare 12.5 L iQ
SYBR Green Supermix, 10.5 L deionized water, 1 L cDNA, and 1 L primer mix
(forward and reverse combined) to a total volume of 20 L.

ELISA
It is important to follow the approved safety protocol when handling human sera.
First, protective goggles (or eyeglasses), double gloves, and lab coat must be worn at all
times. Protective and absorbent cover should be placed over the bench to ensure that if
any serum is spilled, it does not contaminate the work area. Pipet tips that were used to
pipet human sera should be place in a container with bleach to decontaminate them
before discarding in approved container. We preferably thawed human sera by placing
the tubes in ice a few hours before use. If sera must be thawed immediately, put the tube
in 37oC bath but return to ice immediately after thawing. If possible, aliquot serum
samples to minimize thawing and freezing cycles, which may inactivate serum
autoantibodies and other proteins.
Each ELISA Kit used in our studies are purchased with complete instructions
provided. It is important to follow each manufacturers’ instructions as reagents,
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antibodies, incubation times, and required sera volume vary. For example, human PSA
ELISA Kits were purchased from Abnova (Taoyuan City, 320 Taiwan, catalog
#KA0208). The 96-well ELISA plates were pre-coated with goat anti-PSA antibody for
serum PSA detection. Sera were added to the wells in duplicates and circulating PSA was
allowed to bind to the immobilized antibody. Wells were washed to remove unbound
PSA. Monoclonal anti-PSA-horseradish peroxidase conjugate was then added to each
well and allowed to bind PSA. Wells were washed and TMB (3,3’,5,5’
tetramethylbenzidine) reagent (provided in kit) was added to each well followed by
incubation. Color development was interrupted with Stop Solution (provided in kit), and
absorbance was measured by spectrophotometer at 450 nm, with PSA concentration
directly proportional to color intensity. PSA values were calculated from a standard curve
generated using PSA standards provided with the kit.

Cell Migration
In order to evaluate the migratory response of PC3 and DU145 cells following
exposure to Dex, a scratch wound healing assay was performed. Cells were seeded to
confluency in 6-well plates and grown for 24 hours in RPMI 1640 medium supplemented
with 10% charcoal-stripped FBS, with or without 10 nM dexamethasone. Wound areas
were generated (3 per well) using a 200 µl pipette tip by scratching the cell surface
confluent monolayer. Migration of cells into the wound areas was visually tracked using
an Olympus IX70 microscope equipped with SPOT RT3 Imaging System and phase
contrast images were captured at 0, 6, 12, 18, and 24 hours. When capturing 0 hour
images, it is necessary to draw circles using permanent marker around area captured with
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microscope on plastic lid of 6-well plate. These circles are the landmark to use for
subsequent image captures to ensure identical wound areas are compared every 6 hours.
Frequent images were captured in order to track migration prior to complete closure of
the wound areas. The wound recovery rate of migrating cells was measured using ImageJ
Software.

Luciferase Reporter Assay
To conduct future luciferase reporter assays in the lab, it was necessary to expand
plasmids containing the promoter regions of LEDGF/p75 and CLU provided to us from
collaborators. The following instructions outline the steps taken to prepare for luciferase
reporter assay.
Prior to working with bacteria for transformation, it is important to prepare LB
broth and ampicillin plates. Make LB broth according to manufacturer instructions. We
used Fisher (Cat: BP1427-2) 20g LB powder/1 Liter ddH2O. Make broth in flask large
enough for steam overflow in autoclave (i.e. 1000 mL LB broth in 2000 mL Erlenmeyer
flask). Cover flask with foil and place autoclave tape on top. Autoclave on liquid/liquid
setting for pre-set 20 minutes. Store flasks at room temperature to use within 48 hours.
Once LB broth is made, ampicillin plates can be made. The formula to make the gel base
for the ampicillin plates is 20 g LB + 15 g agar/Liter. Place LB and agar in Erlenmeyer
flask and then fill with ddH2O. Stir the mixture with magnetic stir bar for 15 minutes.
Remove stir bar, cover flask opening with foil, and place autoclave tape on top.
Autoclave mixture on liquid/liquid setting at pre-set 20 minutes. Place flask into sterile
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hood and allow flask to cool to warm to the touch (not room temperature as you do not
want mixture to coagulate before pouring). Place sterile cell culture dishes into sterile
hood. For 1 L of LB broth plus agar add 0.1 g ampicillin making final concentration of
100 g/mL. Add ampicillin to cooling Erlenmeyer flask. Pipette 25 mL mixture per cell
culture plate. When pipetting, only remove plate lid slightly to allow space for pipetting.
Leave plates with the top slightly open to dry. When dry, close and put into labeled bag
with gel side of plates facing up. Put plates into 4oC cold room. Empty coagulated
contents of Erlenmeyer flask into trash and then clean flask.
Once the ampicillin plates are made, bacterial transformation with plasmids can
begin. Label Eppendorf tubes (i.e. empty vector, CLU P1, CLU P2). Add 75uL TE buffer
to tubes. Cut plasmids stored on filter paper into 1/4th (e.g. 1 slice of a 4-slice circular
pizza). Place 1/4th circle of plasmid submerged into TE buffer in tubes and vortex for 5
seconds. Leave at room temperature. Place chemically competent bacteria cell tubes into
ice (one tube per plasmid). Label tubes while kept in ice. Set timer for 15 minutes. Place
pre-made ampicillin plates upside down at room temperature. When timer goes off, flick
the bottom of plasmid tubes. Pipette up 5 uL plasmid liquid and transfer into chemically
competent bacteria cell tubes. Pipette up and down without shaking the tube. Keep in ice
30 minutes. Place tubes in hot water bath 42.8O C in Hughes lab for 90 seconds. Place
tubes in ice bucket 2 minutes. Add 1000 uL pre-made LB broth into tubes and shake.
Place tubes in 37OC non-sterile incubator for 15 minutes. (Incubator by the cold room).
Centrifuge tubes 5000 RPM for 2 minutes. Pipette approximately 100 uL of mixture and
drop onto pre-made ampicillin plate. Use sterile plastic streaking wand and transfer cells
by rubbing wand back and forth distributing cells throughout the plate. Store plates
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upside down in 37OC non-sterile incubator overnight. The next morning, check plates to
ensure bacteria colonies have grown. Place parafilm around the edges of the plates and
place upside down in the cold room until the end of the day when bacteria can be seeded
in tubes for expansion.
To expand bacterial growth, be sure to have autoclaved sterile toothpicks, culture
collection tubes with lids, and pair of tweezers. Conduct this procedure later in the day to
allow for overnight incubation/shaking. Perform procedure at open flame. Each collection
tube needs 3mL LB broth plus ampicillin; therefore, make mastermix with total volume
LB broth and ampicillin needed for experiment and vortex to mix. Aliquot 3mL mixture
per tube needed for experiment. (Need 3 tubes per bacterial plate). Flame tweezer point
for 10 seconds and pick up toothpick with tweezer near flame. Softly “scrape”
approximately 6 bacterial colonies (or until visible collection of bacterial colonies at the
tip of the toothpick). Place toothpick with colonies colony-side-down into LB
broth/ampicillin tubes. Place tubes on shaker overnight 225 RPM at 37oC. (Shaker in
autoclave/ice room). The next morning, collect cryovials of 500 L bacterial growth and
add 500 L of 50% glycerol in water for storage in -80oC for future use if needed.
DNA miniprep is the next step to isolate plasmid DNA. We used several kits and
had the most efficient yield with QIAprep Spin Miniprep Kit (Qiagen, Cat:27106).
Briefly, transfer the overnight bacterial culture into centrifuge tubes and pellet by
centrifugation at 8,000 RPM for 3 minutes. Resuspend pelleted bacterial cells in 250 L
Buffer P1 and transfer to a microcentrifuge tube. Add 250 L Buffer P2 and mix
thoroughly by inverting the tube 5 times until the solution becomes clear. Do not allow
the lysis reaction to proceed for more than 5 minutes. Add 350 L Buffer N3 and mix
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immediately and thoroughly by inverting the tube 5 times. Centrifuge for 10 minutes at
13,000 RPM. Apply the supernatant to the QIAprep spin column by pipetting. Centrifuge
for 60 seconds and discard the flow through. Wash the QIAprep spin column by adding
0.5 mL Buffer PB and centrifuge for 60 seconds and discard the flow through. Wash the
QIAprep spin column by adding 0.75 mL Buffer PE and centrifuge for 60 seconds and
discard the flow through. Transfer the QIAprep spin column to the collection tube and
centrifuge for 1 minute to remove residual wash buffer. Place the QIAprep column in a
clean 1.5 mL microcentrifuge tube. To elute DNA, add 50 L Buffer EB or water to the
center of the QIAprep spin column, let stand for 1 minute, and centrifuge for 1 minute.
Nanodrop plasmid sample to determine DNA concentration prior to sending to Eton Bio
for sequencing for verification. Coordinate with Jo-Wen in Dr. Marino De Leon’s lab to
schedule Eton Bio plasmid sequencing. Once plasmid sequence of expanded samples has
been verified to match sequence of original plasmid, further expansion can occur.
To expand bacteria in preparation for DNA maxiprep kit, prepare one 500 mL LB
broth inside 2000 mL Erlenmeyer flask per plasmid sample. At the end of the day, seed
bacterial plates with plasmid-transformed bacteria prepared previously and stored in 80oC prepared in glycerol in cryovials. Follow previous instructions for overnight
incubation. The next morning, place parafilm around the edges of the plates and store
upside down in the 4oC cold room. At the end of the day, thaw bacterial plates in 37OC
non-sterile incubator. Prepare a fresh ampicillin stock as previously described (0.2 g
ampicillin powder reconstituted in 1 mL ddH2O). At open flame, dispense 250 L
ampicillin/ddH2O per 500 mL LB broth flask. Flame bacterial streaking wand, place tip
of wand onto blank space of bacterial plate to cool off the tip to avoid killing bacteria.
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Collect a few colonies until visible on the tip of the wand. Place streaking wand into
Erlenmeyer flask until submerged in the LB broth/ampicillin flask. Keeping flask covered
with foil, shake/rotate overnight at 37oC at 195 RPM. Remove flasks from shaker/rocker
the next morning (not longer than 16 hours) and place in the cold room until conducting
DNA maxiprep the same day.
Because we need to insert plasmids of interest into PCa cells, it is important to
purchase an endotoxin-free maxiprep kit. For this reason, we used the Maxi Fast Ion
Plasmid Endotoxin-Free Kit (IBI Scientific, Cat:IB47124). Briefly, transfer cultured
bacterial cells to a 250 mL centrifuge bottle (bottles in M. De Leon Lab) and centrifuge at
3000 x g (centrifuge in Langridge Lab) for 15 minutes at room temperature to form a cell
pellet. Discard the supernatant completely. During centrifugation, place a plasmid maxi
column in a new 50 mL centrifuge tube and equilibrate the plasmid maxi column by
adding 10 mL of PEQ Buffer. Allow the column to empty completely by gravity flow.
Discard the flow-through and place the plasmid maxi column back in the 50 mL
centrifuge tube and set aside. Add 10 mL of PM1 Buffer (with RNase A added) and 100
L of I-Blue Lysis Buffer to a new 50 mL centrifuge tube. Mix by shaking gently.
Transfer the mixture to the 250 mL centrifuge tube containing the cell pellet and
resuspend by vortex. Transfer the resuspended sample to a new 50 mL centrifuge tube.
Add 10 mL of PM2 Buffer to the resuspended sample then mix gently by inverting the
tube 10 times. Do not vortex to avoid shearing the genomic DNA. Let stand at room
temperature for at least 2 minutes to ensure the lysate is homogeneous. Do not exceed 5
minutes. Add 10 mL of PM3 Buffer and mix immediately by inverting the tube 10 times.
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Do not vortex to avoid shearing the genomic DNA. Centrifuge at 3,000 x g for 20
minutes at room temperature (centrifuge in M. De Leon Lab).
To begin endotoxin removal, invert PER Buffer bottle 3-5 times immediately
prior to use. Transfer the supernatant to a clean 50 mL centrifuge tube. Add 3 mL of PER
Buffer then mix by inverting 5-10 times. Incubate on ice for 30 minutes. Following ice
incubation, transfer the mixture to the equilibrated Plasmid Maxi Column. Allow the
column to empty completely by gravity flow. Discard the flow-through then place the
Plasmid Maxi Column back in the 50 mL centrifuge tube. Wash the Plasmid Maxi
Column by adding 30 mL of PW Buffer and allow the column to empty completely by
gravity flow then discard the flow-through. Place the Plasmid Maxi Column in a clean 50
mL centrifuge tube then add 12 mL of PEL Buffer to elute the DNA by gravity flow.
Discard the Plasmid Maxi Column once it has emptied completely. Add 9 mL of
isopropanol to the eluted DNA. Mix the tube completely by inverting the centrifuge at
15,000 x g for 30 minutes at 4oC (centrifuge in M. De Leon Lab). Carefully remove the
supernatant then wash the DNA pellet with 5 mL of 75% ethanol. Centrifuge at 15,000 x
g for 10 minutes at 4oC. Carefully remove the supernatant then air-dry the DNA pellet for
10 minutes. Once the pellet is dry add 500 L-2mL (or a suitable volume) of fresh
ddH2O collected immediately from water dispenser to ensure the pH is >8. Ambient
ddH2O can quickly cause acidification. Place the tube in a 60oC water bath for 5-10
minutes to dissolve the pellet. We created this water bath by microwaving glass beaker of
water for 1 minute and monitoring temperature with thermometer. Store the dissolved
pellet in 20o C.
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Prior to transfecting PCa cells with DNA plasmids, the plasmids need to be
reconstituted or dried to a 1 g/1 L stock concentration. To accomplish this, we used a
vacuum (2nd floor Mortensen Hall) to evaporate excess water to better concentrate the
plasmid once nanodrop revealed plasmid samples were too dilute. Nanodrop was
repeated every 15 minutes of vacuuming until optimal concentration was reached. To
continue with transfection, we used TransIT-X2 Dynamic Delivery System (Mirus,
Cat:MIR6000). Briefly, plate cells at 15,000 cells/well in 3 mL of complete growth media
per well using 96-well plate (opaque, white tissue-culture plate to minimize cross-talk
between wells and absorption of emitted light during luciferase reporter assay). Culture
overnight at cells should be >80% confluent on day of transfection. Warm TransIT-X2 to
room temperature and vortex gently. Place 10 L/well of serum-free media in a sterile
tube. Add 0.1 L/well DNA plasmid to sterile tube and mix gently by pipetting. Add 0.3
L/well TransIT-X2 to sterile tube and mix gently by pipetting. Incubate at room
temperature for 30 minutes. Add TransIT-X2:DNA complex mixture drop-wise to
different areas of the well. Gently rock the plate for even distribution of complexes and
incubate 24 hours. At 24 hours, spike in 10 nM of Dex per well. To do this, begin with
100 mM Dex stock and mix 1 L Dex in 1 mL charcoal-stripped media for final
concentration of 100 M. From 100 M Dex stock, mix 10 L Dex in 10 mL charcoalstripped media for final concentration of 100 nM. From 100 nM Dex stock, spike in 10
L to each well. Incubate an additional 24 hours to prepare for luciferase reporter assay.
To conduct luciferase reporter assay, we used ONE-Glo Ex system (Promega,
Cat:E8110). Briefly, equilibrate plates to room temperature. Bring ONE-Glo Ex reagents
to room temperature and mix together immediately prior to use. Add 80 L of ONE-Glo
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Ex to each well and incubate samples for at least 3 minutes mixing on an orbital shaker
(300-600 RPM) (shaker in M. De Leon Lab). Measure firefly luminescence using
SpectraMax settings specific for luminescence measuring all wavelengths.

Statistical Analyses
SPSS Statistics Software V22.0 and V23.0 and GraphPad Prism 6 were used for
statistical analyses for these studies. Differences between treatment groups were analyzed
using unpaired Student’s t-test. When comparing multiple groups, ANOVA with
Bonferroni correction was used. P values below 0.05 were considered statistically
significant. All differences highlighted by asterisks were statistically significant as
encoded in figure legends (*P < 0.05; ** P < 0.01; ***P < 0.001; ****P<0.0001).
Additional protocols and experimental details can be found in the laboratory
notebooks stored in the Casiano Laboratory, located in the first floor of Mortensen Hall
in Loma Linda University, Loma Linda, CA. All electronic files pertaining this
dissertation work are stored in the Casiano Laboratory computers and the Casiano
Laboratory external drive memory under the folder Leanne Burnham Casiano Lab Files.
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